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PET is a non-invasive molecular imaging technique that is increasingly being 
used for medical imaging and drug development. Carbon-11 (11C; half-life 20.4 
min) is one of the most commonly used radionuclides for PET molecular imaging. 
11C is usually produced in the form of [11C]CO2 and converted into more reactive 
secondary precursors such as [11C]methyl iodide and [11C]carbon monoxide for 
radiolabelling. Although such secondary precursors are undoubtedly useful, 
given the short half-life of 11C, it would be advantageous to use [11C]CO2 directly 
from the cyclotron without additional time-consuming processing. Therefore, the 
development of radiochemical methods to efficiently radiolabel compounds 
directly with [11C]CO2 for applications in PET neuroimaging is an important goal 
and is the focus of this thesis. 
This work includes the development of novel radiolabelling methodology utilising 
[11C]CO2 for the radiolabelling of molecules based on urea and carbamate 
scaffolds. These functional groups are found in a plethora of biologically active 
molecules and pharmaceuticals. As proof of concept, the utility of the developed 
radiochemistry methods were applied to the synthesis of novel GABA and 
glutamate radiotracers.  
GABA and glutamate are major excitatory and inhibitory neurotransmitters in the 
brain. Although implicated in many diseases, the in vivo function of these 
neurotransmitter system is poorly understood. Their dysfunction are implicated in 
pathologies such as addiction, Alzheimer’s disease, Parkinson’s disease and 
autism. Monitoring the expression of the receptors in vivo and in vitro would 
enable better understanding of these diseases, their progression and treatment. 
The research described in this thesis unveils new methods to radiolabel novel 
molecules for these targets with 11C thereby enabling more opportunities to study 






µmol    micromole 
[11C]CO2  carbon-11 carbon dioxide 
[11C]CH3OTf   carbon-11 methyl trifluoromethansulfonate 
BEMP 2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2 
diazaphosphorine 
DBU    1,8-diazabicyclo[5.4.0]undec-7-ene 
BGO   bismuth germinate 
RCC   radiochemical conversion  
CHI    chromatography hydrophobicity index 
CHI_IAM  immobilised artificial membrane 
CH3CN  acetonitrile  
CNS   central nervous system 
CT    computer technology 
DBAD   di-tert-butyl azodicarboxylate 
DIAD   diisopropyl azodicarboxylate 
DMF    dimethylformamide 
DMSO   dimethyl sulfoxide 
EOB   end of bombardment 
EOS   end of synthesis 
FDG    fluorodeoxyglucose 
GABA   gamma Aminobutyric acid 
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GBq    gigabecquerels 
HPLC   high-performance liquid chromatography 
Hz    hertz  
IC50   the half maximal inhibitory concentration 
IR    infrared 
KeV    kiloelectron volts 
Log P   partition coefficient 
LSO    lutetium oxyorthosilicate 
LYSO   lutetium-yttrium oxyorthosilicate 
mg    milligrams 
mGluR1  metabotropic glutamate receptor 1 
mL    milliliter 
MPa    megapascal  
MRI    magnetic resonance imaging 
nmol    nanomole 
NMR    nuclear magnetic resonance 
s   singlet  
d  doublet 
dd   doublet of doublets 
t   triplet 
1H    proton-1 
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13C   carbon-13 
NSB   non-specific binding 
PBu3   tributylphosphine 
PET   positron emitting tomography 
POCl3   phosphoryl chloride 
ppm    parts per million 
PPh3   triphenylphosphine 
R   organyl group 
RCP    radiochemical purity 
RCY    radiochemical yield 
SA    specific activity 
SPE    solid phase extraction 
T1/2    half-life 
TBAI   tetrabutylammonium iodide 
UV    ultraviolet 












I would like to begin by expressing my sincerest gratitude to Tony Gee for his 
supervision and encouragement. When I joined the Gee group as an MSc student 
4 years ago, my knowledge of PET chemistry was minimal and now, I am able to 
write a thesis. Without Tony’s support and contribution, this project would not 
have been possible. 
I would like to take this opportunity to particularly thank Chloe Child, Rosie 
Henderson, Salvatore Bongarzone and Yolanda Hill for their unwavering support 
and assistance which has truly been invaluable. Cinzia, Julia, Ran and the rest 
of the KCL Imaging Science department have also contributed towards the writing 
this thesis by providing me with the right amount of social support.  
I can’t think of words that are strong enough to describe how grateful I am to my 
parents. Their consistent check-up on my welfare especially during the thesis 
write-up period and their regular consultation has definitely contributed towards 
the successful completion of this thesis, thank you. 
In addition I would like to acknowledge EPSRC for their financial support in 
funding this project; as well as Kings’ College University of London and St. 
Thomas’ Hospital PET Centre for providing me with an enjoyable and pleasant 
environment in which to carry out my project. 
Finally, thanks to you, reader. If you are reading this, you at least read a part of 











Table of Contents 
Abstract ............................................................................................................... 1 
Abbreviations ...................................................................................................... 2 
Acknowledgements  ............................................................................................ 5 
List of publications ............................................................................................ 11 
Chapter 1: introduction  ................................................................................. 12 
1.1    Positron Emission Tomography ............................................................ 13 
1.2    PET applications ................................................................................... 16 
1.2.1     Disease diagnosis and progression ............................................... 16 
1.2.2     Drug development ......................................................................... 17 
1.2.3     Medical research ........................................................................... 18 
1.3    Radiotracers ......................................................................................... 19 
1.4    Radionuclide production ....................................................................... 20 
1.5    Carbon-11 ............................................................................................. 23 
1.6    Summary .............................................................................................. 28 
1.7    Aims and objectives .............................................................................. 29 
1.8    References ........................................................................................... 30 
Chapter 2: [11C]Ureas ...................................................................................... 33 
2.1    Background: ......................................................................................... 34 
2.1.1 Synthesis of urea via isocyanates ................................................. 34 
2.1.2 Synthesis of ureas from carbon monoxide .................................... 35 
2.1.3 Synthesis of ureas from carbon dioxide ........................................ 37 
2.1.4 Synthesis of [11C]urea via [11C]Phosgenes .................................... 41 
7 
 
2.1.5 Synthesis of [11C]urea via [11C]carbon monoxide .......................... 42 
2.1.6 Synthesis of [11C]urea via [11C]carbon dioxide .............................. 46 
2.1.7 Summary ....................................................................................... 50 
 2.2    Aim ....................................................................................................... 51 
2.2    Results and discussion – Asymmetrical [11C]ureas  ............................. 51  
2.3.1 Solvent optimisation ...................................................................... 51 
2.3.2 Mitsunobu reagents optimisation. .................................................. 53 
2.3.3 Temperature and reaction time optimisation. ................................ 54 
2.3.4 Radiolabelling of aliphatic, aromatic and benzylic amines. ............ 55 
2.3.5 Summary ....................................................................................... 58 
2.4 Results and discussion – Symmetrical [11C]ureas. .............................. 58 
2.4.1 Trapping agent, solvent and base optimisation. ............................ 59 
2.4.2 Temperature and concentration optimisation. ............................... 60 
2.4.3 Radiolabelling of various [11C]symmetrical ureas. ......................... 61 
2.4.4 Reaction mechanism: .................................................................... 63 
2.4.5 Trapping of CO2. ........................................................................... 63 
2.4.6 Proposed trapping mechanism ...................................................... 64 
2.4.7 Mitsunobu reaction mechanism ..................................................... 64 
2.5 Conclusion ........................................................................................... 65 
2.6 Methods ............................................................................................... 67 
2.6.1 General synthesis .......................................................................... 67 
2.6.2 Synthesis of reference compounds ............................................... 68 
2.6.3 [11C]CO2 Trapping ......................................................................... 70 
2.6.4 General radiolabelling procedure .................................................. 71 
2.7 References .......................................................................................... 72 
8 
 
Chapter 3: [11C]Carbamates and [11C]Carbonates ....................................... 74 
 Introduction .......................................................................................... 75 
3.1.1 Synthesis of carbamates via isocyanates ...................................... 75 
3.1.2 Synthesis of carbamates via carbon monoxide ............................. 76 
3.1.3 Synthesis of carbamates via carbon dioxide ................................. 79 
3.1.4 Synthesis of carbonates ................................................................ 81 
3.1.5 Synthesis of carbamates and carbonates via CO2 ........................ 83 
3.1.6 Synthesis of [11C]carbonates and [11C]carbamates via the Grignard 
reaction ...................................................................................................... 84 
3.1.7 Synthesis of [11C]carbamates via [11C]phosgenes ......................... 86 
3.1.8 Synthesis of [11C]carbamates via [11C]carbon monoxide ............... 87 
3.1.9 Synthesis of [11C]carbamates via [11C]carbon dioxide ................... 89 
3.1.10   Synthesis of [11C]carbonates ........................................................ 95 
3.1.11   Summary ...................................................................................... 95 
 Results and Discussion........................................................................ 96 
3.2.1 Base optimisation .......................................................................... 96 
3.2.2 Solvent, temperature and time optimisation .................................. 98 
3.2.3 Concentration optimisation .......................................................... 100 
3.2.4 HPLC analysis ............................................................................. 101 
3.2.5 Reaction mechanism ................................................................... 102 
3.2.6 Synthesis of [11C]carbamates ...................................................... 103 
3.2.7 Synthesis of [11C]carbonates ....................................................... 103 
3.2.8 Summary ..................................................................................... 104 
3.2.9 Method 2 ..................................................................................... 105 
 Conclusion ......................................................................................... 109 
9 
 
 Method ............................................................................................... 110 
3.4.1 General ....................................................................................... 110 
3.4.2 Synthesis of reference compounds ............................................. 111 
3.4.3 Radiolabelling procedure ............................................................. 112 
 References ........................................................................................ 114 
Chapter 4: Radiotracer Development .......................................................... 117 
4.1 Introduction ........................................................................................ 118 
4.1.1 CNS radiotracer development ..................................................... 118 
4.1.2 Low non-specific binding and lipophilicity  ................................... 119 
4.1.3 Ease of radiolabelling .................................................................. 122 
4.1.4 High binding potential .................................................................. 122 
4.1.5 Tissue permeability ..................................................................... 123 
4.1.6 Metabolism .................................................................................. 123 
4.1.7 Glutamate receptors .................................................................... 124 
4.1.8 mGluR1 radiotracers ................................................................... 124 
4.1.8 11C radiolabelled mGluR1 radiotracers ........................................ 125 
4.1.8 Summary ..................................................................................... 131 
4.2 Aims ................................................................................................... 131 
4.3 Development of mGluR1 radiotracer ................................................. 132 
4.3.1 Synthesis of compound 1 ............................................................ 133 
4.3.2 Synthesis of compound 15 .......................................................... 137 
4.3.3 The Partition Coefficient. ............................................................. 140 
4.3.4 Radiosynthesis ............................................................................ 143 
4.4 Conclusion ......................................................................................... 147 
10 
 
4.5 Method ............................................................................................... 148 
4.5.1 Synthesis of reference compounds ............................................. 149 
4.5.1 Lipophilicity .................................................................................. 157 
4.5.2 General radiolabelling procedure ................................................ 158 
 References ........................................................................................ 161 
Chapter 5: Conclusion and future work ...................................................... 164 
5.1 Conclusions ....................................................................................... 165 
5.2 Future work ........................................................................................ 168 
5.2.1 mGluR1 radiotracer development................................................ 168 
5.2.2 [11C]CO2 method development .................................................... 172 



















List of publications: 
Rapid and efficient synthesis of [11C]ureas via the incorporation of [11C]CO2 into 
aliphatic and aromatic amines. 
Abdul Karim Haji Dheere, Nadia Yusuf and Antony Gee. 
Chem. Commun., 2013, 49, 8193. 
 
Novel [11C]CO2 Strategy For the Radio-synthesis of [11C]Carbamates and 
[11C]Carbonates.  
Abdul Karim Haji Dheere, Dinah Shakir and Antony Gee. 
Submitted. 
  
Synthesis of 11C-Labelled Symmetrical Ureas via the Rapid Incorporation of 
[11C]CO2 into Aliphatic and Aromatic Amines. 
Abdul Karim Haji Dheere, Carlotta Taddei, Ran Yan, and Antony Gee. 
Submitted. 
Conference abstract publications: 
Rapid incorporation of [11C]CO2 into [11C]carbamates and [11C]carbonates. 
Abdul Karim Haji Dheere and Antony Gee. 
J. Label. Compd. Radiopharm., 2013, 56, S17. 
  
Novel methodology to incorporate [11C]CO2 into aliphatic and aromatic ureas. 
Abdul Karim Haji Dheere and Antony Gee. 




















1.1 Positron Emission Tomography (PET) 
PET is a molecular imaging technique that provides quantitative and functional 
data on physiological processes using molecules labelled with positron-emitting 
radionuclides (often referred to as radiopharmaceuticals or radiotracers).[1] The 
use of PET has dramatically increased in the last decade due to the high 
sensitivity of the technique, making it ideal for in vivo medical diagnosis, medical 
research and drug studies.[1] The ability of PET to carry out studies with tracer 
amounts of radiolabelled molecules enables its utility in in vivo research. 
Typically, less than 10 nmol of the radiotracer is administered to a patient, which 
allows highly potent and toxic compounds to be investigated in subjects without 
manifestation of pharmacological or toxicological effects.[2]  
Positron-emitting radionuclides are inherently unstable due to their neutron 
deficiency. They revert to stable nuclei by emitting a positron and a neutrino. A 
positron is an antiparticle with an electric charge of +1e that annihilates with an 
electron to produce two high energy gamma rays capable of penetrating the body 






 The process of positron decay and detection. 
The annihilation process must satisfy the conservation laws, and as a result, a 
pair of gamma rays that travel in opposite directions with an energy of 511 keV 
are produced. The conservation laws the process must satisfy include the 
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conservation of electrical charge i.e. the net charge before and after must be zero, 
and the conservation of linear momentum and total energy (this forbids the 
creation of a single gamma ray, and results in slight non-collinearity of the two 
annihilation photons)).[4] The pair of gamma rays emitted are detected 
simultaneously by a ring of scintillation detectors surrounding the subject (PET 
scanner, Figure 1.1). Scintillators are materials that, when struck by particles 
such as gamma rays, they absorb the energy and re-emit in the form of light.[5] 
Good scintillators are transparent to their own scintillation light, and have a large 
light output that is proportional to the gamma ray energy. Materials, such as 
sodium iodide doped with thallium, bismuth germanate (BGO), lutetium 
oxyorthosilicate (LSO), and Lutetium-yttrium oxyorthosilicate (LYSO), display 
these properties.[6] Most new PET scanners have LSO/LYSO scintillators as they 
have faster and/or higher light output compared to other scintillators. The light 
emitted by the scintillators is usually detected by a photomultiplier (Figure 1.2).[7]  
 
 
 Schematic diagram of detector block.  
A photomultiplier converts light into an electrical pulse and consists of a 
photocathode, a number of dynodes, and an anode. Firstly, the photocathode 
converts the light produced by the scintillators into electrons. The electrons are 
pulled towards a series of dynodes that in turn, multiply the number of electrons 
that strike them, amplifying the original signal.[8] An anode collects the electrons 












 Schematic diagram of the detector block. 
The electronic pulse from these detectors are deemed to be coincident if they 
occur within a short time interval. A coincident event joins the two relevant 
detectors together to assign a line of response that provides positional 
information from the detected radiation (Figure 1.4). The multiple coincident 
events and the resulting lines of response enable the creation of a map of in vivo 
regional radioactivity concentrations and dynamics (i.e. PET image). 
 


















1.2 PET Applications 
There are three particularly important areas in which the application of PET is 
becoming increasingly used: disease diagnosis and progression, drug 
development and medical research.  
 
1.2.1 Disease diagnosis and progression 
PET is used as a tool to help understand the molecular basis of diseases, 
particularly in neuroscience, cardiology and oncology.[9] A range of carbon-11 
(11C) and fluorine-18 (18F) radiotracers have been developed to image receptors, 
transporters and metabolic processes in vivo.[10] The most common radiotracer 
for medical diagnosis is the 18F-labelled glucose analogue, 
[18F]fluorodeoxyglucose (FDG).[11] Although the hydroxyl group on the 2–carbon 
of a glucose molecule is replaced by a fluorine atom, [18F]FDG enters living cells 
via facilitated transport in a similar manner to glucose. [18F]FDG can be 
synthesised by either nucleophilic or electrophilic fluorination reactions.[12] 
Nucleophilic fluorination using tetra-O-acetyl-mannose triflate as a precursor is 
the most widely used [18F]FDG synthesis method due to high yields and a short 
synthesis time (Scheme 1.1).[12] The stereoselective nucleophilic fluorination 
reaction involves the substitution of the trifluoromethanesulphonate (OTf) group 
with a nucleophilic fluoride-18 anion in an SN2 reaction. 
 
 Synthesis of [18F]FDG from tetra-O-acetyl-mannose triflate.[12] 
Following intravenous administration, [18F]FDG is rapidly distributed to all organs. 
Inside the cell, [18F]FDG is phosphorylated by hexokinase to [18F]FDG-6-
phosphate but unlike glucose, [18F]FDG-6-phosphate is not further metabolised. 
This is due to the replacement of the 2–carbon hydroxyl group with 18F that makes 
the tracer a non-substrate for the subsequent glycolysis pathway. As a result, the 
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18F-labelled tracer accumulates within the cell and can be detected by PET. 
Regions of increased uptake of [18F]FDG reflects elevated glucose transport and 
metabolism.[12]  
Many cancer cells have enhanced glucose transport and metabolism which is 
reflected by a high uptake and accumulation of [18F]FDG in these cells. 
Consequently, the radiotracer has numerous clinical applications such as tumour 
localisation, cancer staging and determining tumour response to therapy.[1] 
 
1.2.2 Drug Development 
Drug development is a lengthy and costly process with a high attrition rate. PET 
is being increasingly used in the selection of novel therapeutics to reduce the 
costs and risks associated with drug development.[13] One of the most valuable 
contributions that PET offers in drug development is providing enough data to 
establish whether a test-compound is suitable as a drug candidate in the early 
stages of the drug discovery process. PET can confirm whether a promising 
compound interacts with a drug target of interest or if it reaches the target organ 
in sufficient concentrations.[14] Consequently, biodistribution and drug-receptor 
occupancy studies are being increasingly utilised by the pharmaceutical industry, 
particularly in organs where it is difficult to perform biopsies to determine drug 
concentrations (for example, the brain).[14]  
A traditional assumption in drug development has been that the concentration of 
a novel drug candidate in tissue is similar to that measured in the blood. However, 
this assumption is known to be untrue for many drugs. An error in the assumption 
of tissue-drug concentrations could lead to an overdosing or underdosing of the 
drug. PET can be used to determine both the blood/plasma and target tissue 
concentrations of the labelled drug candidate allowing more efficient drug dosing 
paradigms.  Moreover, PET can also determine if sufficient concentrations of the 




After a drug candidate is radiolabeled (isotopic labelling) and administrated, PET 
scans can demonstrate its presence in organs such as the brain, confirming 
blood-brain-barrier penetration.[15][16] 
Receptor occupancy is another parameter in which PET is greatly utilised during 
the early stages of drug development.[17] Receptor occupancy refers to the 
percentage of a receptor population that is occupied by the drug at a specified 
dose or concentration in plasma.[18] The importance of determining the receptor 
occupancy has been elegantly demonstrated by PET studies of antipsychotic 
drugs acting on dopamine D2 receptors.[19] Side effects were observed at a D2 
receptor occupancy higher than 80 %, increasing the incidence of extrapyramidal 
symptoms. However using PET, it was demonstrated that the drug-induced side 
effects could be avoided by reducing the D2 receptor occupancy to 65 – 80 % 
while retaining the beneficial anti-psychotic effect.[19] 
 
1.2.3 Medical research 
The function and expression of receptors, enzymes, transporters and other 
proteins are often altered in disease states and PET can help to identify them.[8] 
The ability of PET to monitor radiotracers that interact with proteins involved in 
diseases has provided a unique tool for medical research. Alzheimer’s disease is 
one of the main diseases in which PET is being extensively utilised. Amyloid 
plaques and neurofibrillary tangles are pathological markers found in Alzheimer’s 
disease brains. It is thought that these plaques are present as many as 10 years 
before Alzheimer’s clinical symptoms appear. In the last few decades, PET 
radiotracers that bind to amyloid plaques have been developed (Figure 1.5).[20] 
Subjects with Alzheimer’s disease showed a two fold increase in the retention of 




 The chemical structure of [11C]PIB and PET scans showing the retention of 
[11C]PIB in the brain. Images from two control individuals are shown in the top row while 
bottom row shows the corresponding images from Alzheimer disease individuals. The 
scale bar indicates the relative levels of PIB standardised uptake values.[20]  
In addition to its application in the neurosciences,[22] PET is also being actively 
utilised in cardiology[23] and oncology[24] research. 
 
1.3 Radiotracers 
Enzymes, receptors and metabolic substrates are some of the many biological 
targets/ processes that can be potentially imaged using PET.[15] To image these 
biological processes, a successful radiotracer that has a high signal-to-noise ratio 
in vivo must be established. There are many similarities between drug and 
radiotracer development, as well as many differences. In drug development, drug 
candidates fail for various reasons including low bioavailability, toxicology and 
inappropriate therapeutic windows. These are not challenges encountered when 
developing a radiotracer as the tracers are usually administrated intravenously in 
high specific activities. Specific activity is defined as the amount of radioactivity 
per mole of compound (GBq/µmol).[1] Radiotracers that bind to specific receptors 
present in finite concentrations are required to have a high specific activity, 
typically in the range of 50 – 500 GBq/µmol to ensure that the receptors are not 
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saturated. A radiotracer with a high specific activity (i.e. that does not saturate 
receptors) enables it to be studied in a subject without perturbing the biological 
system. Another challenge encountered in radiosynthesis with short-lived 
radionuclides is the reaction time. Whilst with traditional chemistry, the synthesis 
time of a drug-like molecule can range from minutes to a few days, radiolabelling 
reactions are generally short. Rapid and efficient purification methods are also 
required. Purification of radiolabelled compounds is usually performed using 
solid-phase extraction or semi-preparative HPLC equipped with UV and radio 
detectors.   
 
1.4 Radionuclide production 
The synthesis of radiotracers for PET starts with the production of the 
radionuclides. Cyclotrons are used to produce the majority of PET 
radionuclides.[25] A cyclotron is a particle accelerator invented by E. Lawrence in 
1932. It functions by using a high frequency alternating voltage that is applied 
between two metal electrodes called “dees”. The two dees are placed in a 
vacuum facing each other with a narrow gap in-between (Figure 1.6). Charged 
particles are ejected into the centre of the gap and accelerated from the centre 
into the dees. A large electromagnet is located above and below the two dees 
which cause the particle’s path to bend in a spiral as they travel.[8]  
 





Initial position of the 
charged particles 
Charged particles exit 
the cyclotron  Dees 
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Each time the particle passes though the gap between the dees, the polarity of 
the alternating radiofrequency voltage reverses, accelerating the particle into the 
opposite dee. As a result, particles complete one circuit per frequency cycle. 
When the particles reach the edge of the cyclotron, they are steered out of the 
cyclotron toward the target where the radionuclide is to be produced. Negative-
ion cyclotrons are most commonly used, due to their higher efficiency and 
reduced cyclotron activation. The accelerated particles in these cyclotrons are 
negatively charged ions (e.g. H atom with 2 electrons). When the negatively 
charged ions reach the end of their path, they pass through a thin carbon foil 
which removes electrons, leaving positively charged protons. The change of 
charge causes the movement of the particles to revert and travel in the opposite 
direction. As a result, the positively charged proton is steered out of the cyclotron 
to hit a target containing the material to be bombarded to produce the product 
PET radionuclide.[8] 
The characteristics of some common positron-emitting radionuclides are shown 
in Table 1.1. 11C is prepared by the proton bombardment of nitrogen-14 gas, 
fragmenting to 11C and an α-particle. Similarly, 13N and α-particles are produced 
by the cyclotron bombardment of accelerated protons onto an oxygen-16 target. 
18F can be produced by bombarding neon-20 (20Ne) with deuterons or by 
bombarding 18O with protons.[1, 25] 














11C 20.4 14N(p,α)11C 
13N 9.97 16O(p,α)13N 






These radionuclides have short half-lives and therefore must be produced at the 
point of use. Half-life in nuclear chemistry is the time required for half of the 
unstable radionuclides in a sample to undergo radioactive decay. Radioactive 





 Exponential radioactivity decay curve showing a 2 hour half-life. 
 
The number of atoms undergoing radioactive decay in a given time depends upon 
the number of radionuclides present at that time and the decay constant. The 
exponential decay process can be expressed by the differential equation 
(equation 1.1), where N is the quantity of the radionuclide, and 𝜆 is the 
exponential decay constant. The negative sign is inserted to indicate that N 
decreases with time. 
𝑑𝑁
𝑑𝑡
=  −𝜆𝑁 
Equation 1.1 Differential equation expressing exponential decay in terms of the exponential 
decay constant. 
Equation 1.1 can be integrated and rearranged to form equation 1.2, where N(t) 
is the quantity of the radionuclide at a given time t, N0 is the quantity of the 

































Equation 1.2 The equation to determine the quantity of a radionuclide at a specific time t. 
Half-life is defined as the time taken for the radioactivity of a radionuclide to decay 
to half of its original value and therefore, Nt/No becomes ½. To calculate the half-
life, equation 1.2 can be simplified to become equation 1.3. 




Equation 1.3 The equation to determine half-life. 
 
1.5 Carbon-11 
11C is one of the most commonly used PET radionuclides, with numerous 
radiotracers having been developed for imaging metabolic, enzymatic and 
receptor-mediated function in vivo.[26] The presence of carbon in all naturally 
occurring organic compounds makes 11C an attractive positron emitter: 
substituting the naturally-abundant carbon-12 (12C) in biologically active 
molecules with radioactive 11C has no effect on the chemical and the biological 
activity of the molecule. Furthermore, the short half-life of 11C (t1/2 = 20.4 minutes) 
enables the collection of a sufficient amount of PET data while keeping the 
radiation dose to a minimum. It also permits repeated studies in the same subject 
on the same day.  
11C is produced by a cyclotron in the form of [11C]carbon dioxide ([11C]CO2) or 
[11C]methane ([11C]CH4).[25] These cyclotron-produced molecules are referred to 
as primary synthons. Generally, the primary synthons are converted into more 
reactive secondary synthons such as [11C]methyl iodide ([11C]CH3I),[27] 
[11C]methyl triflate ([11C]CH3OTf),[28] [11C]carbon monoxide ([11C]CO),[29] cyanide 
([11C]CN)[30] and phosgene ([11C]COCl2)[31] for further incorporation into a 




 Some of the most common 11C synthons. 
There are a limited number of methods available that use [11C]CO2 directly for 
radiolabelling, mainly due to the chemical properties of CO2.[32] CO2 has an 
electron deficient central carbon and therefore acts as a weak electrophile. As a 
result, the molecule has an affinity for electron-donating reagents and 
nucleophiles.[33] However, due to the thermodynamic and kinetic stability of CO2, 
the compound is poorly reactive. High pressures, high temperatures and 
catalysts (e.g. palladium) are required to activate the molecule and form a more 
reactive species.[34] 
In traditional organic chemistry, CO2 has been used to access compounds that 
contain carbonyl groups, a common structural element of biologically active 
molecules. Furthermore, CO2 is widely available and therefore, it has become an 
attractive and challenging synthesis reagent. Various methods to incorporate 






 Chemical structures that can be synthesised using CO2.[35] 
The most notable of these is the Grignard reaction which involves the conversion 
of alkyl and aryl magnesium halides to carboxylic acids (Scheme 1.2).[36] 
 
 The reaction between Grignard reagent and CO2. 
Other examples of reactions that use CO2 for the synthesis of a target compound 
include the synthetic route proposed by Tran-Vu and Daugulis [37] (Scheme 1.3). 
The reaction incorporates CO2 into aryl iodides sufficiently (> 50 %) by employing 
copper iodide/TMEDA in DMSO solvent for the synthesis of carboxylic acids. 
 
 Copper-mediated carboxylic acid synthesis via CO2.[37] 
Another method that uses CO2 is reported by Tominaga et al.[38] The synthesis is 
catalysed by a Ruthenium (Ru) complex in an ionic liquid and converts alkenes 






 Ruthenium-mediated alcohol synthesis via CO2.[38] 
A notable feature of this synthesis strategy is that it produces the target product 
with yields of over 70 %. However, high pressures (4.0 MPa) and temperatures 
(160 oC) are required. 
The use of CO2 in synthetic methods has increased over the last few years. Some 
examples of reactions that use CO2 have been described above. Other reactions, 
particularly for the synthesis of ureas, carbamates and carbonates, will be 
discussed in chapter 2 and 3.[34b, 39]  
 
1.5.1 [11C]CO2 method development 
Generally, to develop a radiolabelling methodology, a traditional organic 
chemistry method is used as a starting point. However, when adapting the 
traditional method to a radiolabelling reaction, the radionuclide’s half-life, reagent 
concentration and reaction time must be taken into account. 
1.  [11C]CO2 trapping: Before bubbling the [11C]CO2 into a reaction mixture, 
the gas is usually concentrated. There are two methods available to 
concentrate the [11C]CO2 that is released from the cyclotron target.[32] 
Cryogenic trapping consists of passing the produced gasses though a 
vessel cooled by liquid nitrogen. Condensable gases such as [11C]CO2 are 
trapped within the vessel while non-condensable gases are removed. The 
second method immobilises the [11C]CO2 on a solid material such as 
molecular sieves. The release of [11C]CO2 can be controlled 
thermodynamically and with a low carrier gas volume.[32]  
2. Trapping reagents: Due to [11C]CO2 being produced in low concentrations 
and in a gaseous state, it has to be trapped within the reaction solution 
efficiently. To increase the trapping efficiency, a trapping reagent can be 
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added to the reaction mixture. DBU and BEMP have recently been 
developed as in situ [11C]CO2 trapping agents.[40] 
Although traditional organic synthesis methodologies are used as a starting point 
when translating these methods for use in radiolabelling, the reactions require 
further optimisation i.e. the reaction is examined under different solvents, 
temperatures and concentrations. This is necessary because of the sub-
stoichiometric concentration of 11C used in a reaction. The [11C]CO2 radiolabelling 
reaction developed by Riss et al.[41] is an example of a radiolabelling methodology 
that used traditional organic chemistry as a starting point. The original organic 
chemistry reaction was established by Takaya et al.[42] The reaction incorporated 
CO2 into organoboronic esters to form carboxylic acids. Optimum reaction 
conditions were obtained when CuI was used as catalyst, bisoxazoline was used 
as a ligand, CsF was used as a base and DMF as a solvent. The reaction mixture 
was heated at 90 oC for 10 hours (Scheme 1.5). 
 
 The synthesis of carboxylic acids from boronic esters via CO2.[42] 
The analogous radiochemical synthesis also used CuI as a catalyst and DMF as 
a solvent (Scheme 1.6), however, additional reagents were required: 
Tetramethylethylenediamine (TMEDA) to obtain a high [11C]CO2 trapping 
efficiency, and potassium fluoride (KF) and 2.2.2-cryptand to increase the yield 
and the rate of reaction.[41] 
 
 The synthesis of [11C]carboxylic acids from boronic esters via 
[11C]CO2.[41] 
The reason for these modifications is that [11C]CO2 is used on a nanomolar (nmol) 
scale and at sub-stoichiometric concentrations while in traditional chemistry, the 
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CO2 is used in excess. Other examples of traditional organic chemistry that has 
been translated to radiolabelling are discussed in Chapters 2 and 3. 
Direct radiolabelling with [11C]CO2 has the potential advantage of avoiding the 
time-consuming production of secondary labelled synthons enabling the 
opportunity to radiolabel molecules of interest rapidly. However, the use of 
[11C]CO2 is limited by its stability. Further, radiolabelling with the primary synthon 
is prone to contamination from atmospheric CO2.[32] Non-radioactive CO2 
competes with radioactive [11C]CO2 in labelling reactions potentially resulting in 
a low specific activity. 
 
1.6 Summary  
PET is a non-invasive molecular imaging technique that is used for medical 
diagnosis, medical research and drug development. 11C is one of the most 
commonly used radionuclides and it is produced by a cyclotron in the form of 
[11C]CO2. The primary synthon is usually converted into other forms such as 
[11C]CH3I for incorporation into a molecule of interest. Further, [11C]CO2 is 
thermodynamically and kinetically stable which makes it unreactive and as a 
result, there are only a limited number of radiolabelling methods available that 
incorporates it directly into target compounds. Due to the half-life of 11C, it is 
beneficial to incorporate the primary synthon directly. Recently, novel strategies 
that activate CO2 and incorporate it into different structures have been 
developed.[40] These methods can be used as a starting point for developing rapid 
radiolabelling reactions. Developing novel [11C]CO2 reactions is of great interest 
as it would enable the radiolabelling of compounds that are not accessible by 








There are limited number of [11C]CO2 radiolabelling methodologies and therefore, 
the development of novel methods is of interest. Chapters 2 and 3 of this thesis 
focuses on the development of novel radiolabelling chemistries. This work 
includes the development of radiolabelling methodologies utilising [11C]CO2 for 
the radiolabelling of molecules based on urea and carbamate scaffolds. These 
functional groups are found in a plethora of biologically active molecules and 
pharmaceuticals. In chapter 4, the utility of the developed radiochemistry 
methods were applied to the synthesis of novel glutamate radiotracers. 
Glutamate receptors are major excitatory neurotransmitters in the brain. Although 
implicated in many diseases, the in vivo function of these neurotransmitter system 
is poorly understood. Their dysfunction are implicated in pathologies such as 
addiction, Alzheimer’s disease, Parkinson’s disease and autism. Monitoring the 
expression of the receptors in vivo and in vitro would enable better understanding 
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2 Chapter 2 
2.1 Background 
Ureas are a stable class of compounds that contain two nitrogen atoms joined 
together by a carbonyl group (Figure 2.1). The functional group is found in a 
plethora of pharmaceutical compounds, agrochemicals and endogenous 
compounds. Numerous methods for the synthesis of urea have been 
developed.[1]  
 
Figure 2.1 Urea-containing pharmaceutical compounds.  
2.1.1 Synthesis of ureas via isocyanates  
Isocyanates are reactive functional groups that can be synthesised from various 
groups such as carboxylic acids and amines. When carboxylic acids are reacted 
with acid chlorides in the presence of sodium azide, an isocyanate intermediate 
is produced via the Curtius rearrangement (Scheme 2.1).  
 
Scheme 2.1 The synthesis of isocyanates from carboxylic acids.[1] 
The isocyanate intermediate is prone to nucleophilic attack from amines to form 
ureas (Scheme 2.2). This is one of the common methods used for the synthesis 
of ureas as it produces the target compound efficiently at room temperature.  
 
Scheme 2.2 The synthesis of ureas from carboxylic acids via isocyanates.[1] 
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2.1.2 Synthesis of ureas from carbon monoxide 
Carbon monoxide (CO) gas can be used for the synthesis of ureas. In general, 
synthesis with CO requires specialised equipment as reactions are performed at 
high pressure. However, more recently, new methods for CO incorporation into 
ureas at lower pressure have been developed.[2] 
The methods available to incorporate CO into urea molecules are usually 
mediated by transition metals such as palladium (Pd),[3] tungsten (W),[4] and gold 
(Au).[5] CO is an electron donor which enables it to act as a ligand for these metals 
and subsequently it can be inserted into target compounds. 
Troisis et al.[3] developed a simple synthetic procedure that uses CO for the 
preparation of benzo-fused five- and six-membered heterocycles in yields of > 70 
% (Scheme 2.3). The reaction is of interest as heterocyclics such as 
benzimidazol-2-ones and its derivatives are important pharmacophores.  
 
Scheme 2.3 The synthesis of benzimidazol-2-ones using CO.[3] 
The palladium catalysed carbonylation reaction is performed at high pressure 
(2.75 MPa) and requires a base for deprotonation as shown in scheme 2.4. The 
starting material is believed to form a complex with Pd(0) which enables CO 
insertion between X and Pd to form intermediate 1 (X is either S, O or NH). 
Although it is reported by Troisis et al.[3] that the deprotonation of the YH is the 
next step (Y is either S, O or NH), the deprotonation is most likely to take place 
after the formation of the 6 membered cycle (intermediate 2, Scheme 2.4). This 
is due to the pKa of Et3N being too low to deprotonate Y when it is an amine. 




Scheme 2.4 Palladium-mediated urea synthesis.  
Another method that incorporates CO into amines for the synthesis of ureas was 
developed by Zhang et al.[4] The reaction is catalysed by the tungsten 
hexacarbonyl [W(CO)6] in the presence of 4-dimethylaminopyridine (DMAP) 
base, Iodine (I2) and CO (Scheme 2.5).  
 
Scheme 2.5 Tungsten catalysed asymetrical urea asymmetrical by CO incorporation. [4] 
The reaction is believed to proceed through isocyanate intermediate formation. It 
was reported that no target product was formed when carbonylation of secondary 






2.1.3 Synthesis of ureas from Carbon dioxide 
Peterson et al.[6] developed the use of 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) 
and the Mitsunobu reaction with CO2 for the synthesis of ureas. DBU was used 
as a CO2-activating agent to form an unstable in situ intermediate (Scheme 2.6). 
Mitsunobu reagents were used as a dehydrating agent to form the corresponding 
isocyanate intermediate which reacts with a secondary amine to form the final 
urea product.  
 
Scheme 2.6 The synthesis of ureas via isocynate intermediate.[6] 


































The reaction can be used to incorporate CO2 into aliphatic, aromatic and benzylic 
amines to form ureas in high yields (Table 2.1). However, the reaction is limited 
by the isocyanates intermediate formation, i.e., one of the reacting amines must 
be a primary amine.  
Mizuno et al.[7] also developed a method using DBU for the synthesis of 
quinazoline-2,4-dione (Scheme 2.7). Quinazoline-2,4-diones are key 
intermediates for producing pharmaceutical compounds such as Zenarestat (an 
aldose reductase inhibitor) and 3-ethyl-8-[2-(4-
hydroxymethylpiperidino)benzylamino]-2,3-dihydro-1H-imidazo[4,5-
g]quinazoline-2-thione dihydrochloride (a cyclic nucleotide phosphodiesterase 5 
inhibitor).  
 
Scheme 2.7 The synthesis of Zenarestat by CO2 incorporation.[7] 
The reaction produces the corresponding product efficiently under mild conditions 
(Scheme 2.8). Similar results are observed when Cs2CO3 is used for the 
synthesis of quinazoline-2,4-dione.  
 
Scheme 2.8 A reaction pathway for the synthesis of quinazoline-2,4-diones as proposed by 
Mizuno et al..[7] 
 
In the presence of an amine, a base and carbon-14 CO2, POCl3 can also be used 
for the synthesis of urea.[8] The reaction proceeds through an isocyanate 
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intermediate when primary amines are reacted with POCl3, while secondary 
amines proceed via a carbamyl chloride. The isocyanate intermediate was 
observed when the reaction was performed using [14C]CO2 at -78 oC. Good to 
moderate isocyanate yields were obtained when aniline bearing electron 
withdrawing groups were reacted (Table 2.2).  
Low yields (10 %) were observed when the electron withdrawing ester group was 
present while nitro-containing aniline did not produce the target urea due to 
insufficient CO2 trapping (Table 2.2, Entries 3 and 4). The isocyanate yield could 
be improved by the addition of N-dicyclohexyl-N',N',N",N"-tetramethyl guanidine 
(CyTMG) and pyridine. It is believed that increased yields are obtained due to the 
base combination providing additional stabilization of carbamate salts (Scheme 
2.9).  





























                               
Scheme 2.9 The synthesis of ureas in the presence of POCl3 
In a similar method, the combination of CyTMG and pyridine allowed secondary 
amines to form carbamyl chlorides with moderate yields of 20 to 35 %. Warming 
the isocyanate species from - 78 oC to - 20 oC with the addition of further amine 
produced the target urea.   
The method was used to label L-7400937 (a CCK B antagonist) with carbon-14 
(14C) with an overall yield of 70% based on the starting [14C]CO2 (Scheme 2.10).[8]  
 
Scheme 2.10 Synthesis of carbon-14 labelled L-740,093. 
Since urea structures are common motifs in biologically active molecules (see 
Figure 2.1) the development of methods for the radiolabelling of the functional 
group with PET radionuclides is of considerable interest. The urea structure has 
been radiolabelled previously using three different 11C synthons: [11C]COCl2, 





2.1.4 Synthesis of [11C]ureas via [11C]Phosgenes 
[11C]phosgenes ([11C]COCl2) are highly reactive species that can be synthesised 
from cyclotron-produced [11C]methane via a [11C]carbon tetrachloride 




Scheme 2.11 The synthesis of [11C]COCl2 from [11C]CH4 via [11C]CCl4 and from [11C]CO2 via 
[11C]CO. 
Numerous compounds have been radiolabelled with [11C]COCl2 for in vivo and in 
vitro imaging. Sorafenib, a multi-kinase inhibitor used for the treatment of cancer 
is one such example (Scheme 2.12).[10] The reaction proceeds through the 
formation of an isocyanate intermediate and forms the corresponding product 
rapidly at room temperature. 
 
Scheme 2.12 the radiolabelling of Sorafenib with [11C]COCl2.[10] 
Interestingly, when the aniline is reacted with [11C]COCl2 at room temperature, 
the [11C]isocyanate is the major product detected by radio-HPLC (Scheme 2.13). 
However, heating the reaction at 50 oC results in the formation of the 11C-labelled 




Scheme 2.13 Reaction products at different temperatures. 
[11C]COCl2 has also been used to radiolabel Ketanserin (a serotonin antagonist) 
with moderate RCY of 25 to 50 % (corrected for radioactive decay from 
[11C]COCl2).[10] 
 
Scheme 2.14 The preparation of [11C]Ketanserin 
Many tracers have been radiolabelled with [11C]COCl2 and although 
radiolabelling is rapid and efficient, routine synthesis of the synthon is challenging 
and requires specialised equipment. Furthermore, [11C]COCl2 is obtained in low 
radiochemical yields (RCY) via multistep syntheses, thereby restricting its 
widespread use. 
 
2.1.5 Synthesis of [11C]ureas via [11C]carbon monoxide 
[11C]Carbon monoxide ([11C]CO) has been used to radiolabel ureas efficiently. 
The synthon is typically produced by passing [11C]CO2 through zinc (Zn) or 
molybdenum (Mo) at 290 oC and 850 oC respectively.  
One of the main challenges faced when using [11C]CO is its low solubility in 
organic solvents. This is generally counteracted by recirculation of [11C]CO 
through the reaction or by performing the reaction under high pressure.[9, 11] More 
43 
 
recently, metal-ligand complexes have been used to trap [11C]CO in the reaction 
mixture[12] and as a consequence, carbonylation is becoming a more versatile 
11C-labelling strategy. Several radiolabelling methodologies are available for 
radiolabelling ureas with [11C]CO, enabling the synthesis of many different 
compounds. [13] 
Rhodium (Rh) and Pd-mediated carbonylation reactions are the most common 
strategies used to radiolabel with [11C]CO. Langstrom et al.[13a] developed a 
method using a Rh(l)-complex to mediate the radiolabelling of ureas with [11C]CO 
using amines and azides (Table 2.3). 
The reaction tolerates both acidic and basic substituents. However, 
nucleophilicity has a major effect on the RCY. As expected, high RCYs were 
observed for strong nucleophiles such as phenylazide (Table 2.3, Entry 2) and 

























a Determined by Radio-HPLC. 
This method was used for the radiolabelling of Tolbutamide (a potassium channel 
blocker) in RCY of 83 ± 1 % (corrected for decay from [11C]CO).[13a]  
 
Scheme 2.15 The radiolabelling of Tolbutamide using [11C]CO.[13a] 
 


















In 2014, Kealey et al.[13b] established a Pd-mediated oxidative carbonylation 
method for the synthesis of asymmetrical [11C]ureas using [11C]CO. Copper(I) 
Tris(pyrazolyl)borate complexes (CuTp(CO)) was used for trapping The [11C]CO 
within the reaction mixture. 
High RCYs were observed when primary amines were reacted with cyclic amines 
while low yields were observed when aromatic amines were reacted due to their 
weak nucleophilicity (Table 2.4). The reaction is believed to proceed via the 
formation of [11C]isocyanate intermediate and therefore, secondary amines 
cannot be used to form the corresponding [11C]urea.  
 









a Determined by Radio-HPLC 
The attractive feature of the synthesis methodology is the simplicity of the 
reaction set-up compared to other [11C]CO methods. The radiolabelling set-up 
enables the reaction to be performed in a synthesis laboratory using common 
apparatus. However, the reaction is limited by the use of large excess of 
precursor (45 - 90 µmol) in order to obtain to obtain the target product efficient. 












2.1.6 Synthesis of [11C]ureas via [11C]carbon dioxide 
Schirbel et al.[14] developed the first method to radiolabel symmetrical ureas using 
[11C]CO2. Similar to most other methods for urea synthesis, the reaction is 
believed to proceed via the formation of an isocyanate which undergoes 
nucleophilic addition with an amine to form the symmetrical urea (Scheme 2.16). 
The reaction temperature was found to be a critical factor. The best RCYs were 
observed at -20 oC. 
 
Scheme 2.16 The synthesis of [11C]aromatic urea via [11C]CO2. 
High RCYs of over 60 % were observed for aromatic and benzylic symmetrical 
[11C]ureas (Table 2.5, Entries 1 and 2). However, low RCYs were observed when 
aliphatic amines were used for the synthesis of [11C]ureas (Table 2.5, Entry 3). 







a Determined by HPLC. [14]  
Wilson et al.[15] used a one-pot synthetic method to incorporate [11C]CO2 into 
urea-containing compounds using 2-tert-nutylimino-2-diethylamino-1,3-
dimethylperhydro-1,3,2 diazaphosphorine (BEMP) as a trapping agent in the 
presence of POCl3 (Table 2.6).  



























a Determined by HPLC. 
A notable feature of this method is that the overall synthesis time was under five 
minutes. The radiolabelling procedure used cyclotron-produced [11C]CO2 directly 
to radiolabel aliphatic and benzylic amines to form [11C]ureas in good to excellent 
RCY (47% - 86%).  
The radiolabelling procedure was limited by low yields for anilines (6 %) due to 
their reduced nucleophilicity.  
The reaction is believed to proceed via an [11C]isocyanate intermediate when a 
primary amine is reacted with [11C]CO2. Reactions with secondary amines 
resulted in the formation of N,N-disubstituted [11C]ureas. The asymmetric ureas 
are believed to proceed via an [11C]carbomyl chloride intermediate (Scheme 
2.17).[15] 
















Scheme 2.17 Proposed methodology for [11C]urea synthesis via isocyanate.[15] 
 
The method was used for the radiolabelling of PF-04457845 (a fatty acid amide 
hydrolase inhibitor) to give an overall yield of 4.5 ± 1.3% based on starting 
[11C]CO2 (uncorrected for decay) and a radiochemical purity of > 95% with a total 
synthesis time of 25 ± 2 min (Scheme 2.18).[16] 
 
 
Scheme 2.18 The synthesis of [11C]PF-04457845.[16] 
The method has also been used to radiolabel AR-A014418 (a GSK-3 inhibitor).[17] 
The overall yield was 8.3 ± 3.9% based on starting [11C]CO2 (uncorrected for 
decay), specific activity of 150 ± 40 GBq/µmol and a radiochemical purity of > 95 
% with a total synthesis time of 28 minutes including formulation (Scheme 2.19). 
 
Scheme 2.19 The synthesis of [11C] AR-A014418.[17] 
Another reported method to radiolabel ureas was via the condensation of 
phosphinimines with [11C]CO2.[18] The method can be used to radiolabel aromatic 





Scheme 2.20 [11C]urea synthesis using triphenylphosphinimines and [11C]CO2.[18] 
The [11C]CO2 was trapped in a solution of THF at – 60 oC in the presence of 
phosphinimine and an amine. Subsequently the solution was heated to 60 oC 
for six minutes and the resulting mixture was analysed by radio-HPLC. Aliphatic 
amines gave RCY of 45 to 49 % (determined using HPLC) while aniline gave 
only 8 % RCY (Table 2.7). 
 













a Determined by radio-HPLC 
 
The radiolabelling reaction is limited by the availability of phosphinime 
compounds. Limited numbers of phosphinime compounds are commercially 

















A plethora of molecules containing the urea functional group and possessing a 
wide range of pharmacological properties can be found in the literature.[20] 
Radiolabelling this important class of compounds with PET radionuclides may 
help in early diagnosis, monitoring pathophysiology and offer the opportunity to 
deepen our understanding of drug-receptor interactions. 
[11C]COCl2, [11C]CO and [11C]CO2 have been used to radiolabel ureas. Each 
synthon has its advantages and limitations. [11C]COCl2 reactions are rapid and 
efficient however, the preparation of the synthon is challenging. While [11C]CO 
methods work well, few laboratories have the infrastructure required to produce 
[11C]CO routinely, limiting it’s widespread utility. [11C]CO2 is poorly reactive and 
as a result, only a limited number of methods using it directly in radiolabelling 
reactions are available. 
In the past few years, novel methods to radiolabel compounds with [11C]CO2 have 
been developed. There are two methods available to radiolabel asymmetrical 
ureas with [11C]CO2 but both methods are limited to aliphatic and benzylic 
amines. Low RCYs are observed for the synthesis of aromatic ureas. Developing 












The aim of this chapter is to develop a one-pot radiolabelling methodology that 
incorporates [11C]CO2 directly into aliphatic, benzylic and aromatic ureas. It has 
been shown that CO2 can be trapped within a reaction mixture by using DBU and 
an amine.[21] It has also been shown that Mitsunobu reaction can be used to 
convert nonradioactive carbamate ion to urea. The project aims to combine the 
trapping with DBU and Mitsunobu reaction for the synthesis of [11C]ureas.  
 
2.3 Results and discussion – Asymmetrical [11C]ureas 
Model reactions were initially conducted using nonradioactive CO2. [6] Compound 
1 was subsequently chosen as the initial model reaction for optimisation with 
[11C]CO2 (Scheme 3.21). 
 
Scheme 3.21 Synthesis of the reference compound (compound 1). 
 
2.3.1 Solvent optimisation 
Initially, the radiolabelling reactions were carried out in various solvents including 
DMF, DMSO, dioxane and toluene at 40 oC with the aim to identify the best 
solvent for the reaction (Table 2.8). These solvents were selected as they have 
been reported to trap [11C]CO2 in the presence of DBU or possess functionalities 
that have previously demonstrated to trap non-radioactive CO2. Polar solvents 
(DMF, DMSO and CH3CN) trapped the [11C]CO2 more efficiently than non-polar 
solvents such as toluene and dioxane. The high trapping by the polar solvents is 
consistent with the result previously obtained by Hooker et al.[22] whereby CH3CN 
trapping the highest radioactivity followed by DMF and DMSO. When [11C]CO2 
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was bubbled directly into the CH3CN reaction mixture (Table 2.8, Entry 1), over 
95 % of the produced [11C]CO2 was trapped, while DMSO and DMF trapped less 
efficiently (80 - 90 %). Dioxane and toluene trapped the [11C]CO2 to a lesser 
degree (< 20 %).  
Co-elution with reference compound confirmed the synthesis of [11C]compound 
1 in moderate radiochemical conversions (RCC) when CH3CN was used as 
solvent (46 %). The RCC was estimated by radio-HPLC and defined as the area 
under the [11C]urea peak expressed as a percentage of the total 11C labelled peak 
areas observed in the chromatogram. DMF and DMSO also produced the 
radiolabelled compound 1 but with poor RCCs of 13 % and 18 % respectively 
while dioxane and toluene resulted in no product formation.  
Low yields for DMF and DMSO were observed presumably due to the Mitsunobu 
reagents not being fully soluble in these solvents leading to low yields. The 
highest RCCs were obtained when CH3CN was used, and therefore it was 
selected as the solvent of choice for subsequent reactions. 
 









a Screening conditions: Benzylamine (18.3 µmol), tetrahydroisoquinoline (27.5 µmol), DBU (0.8 
µmol), Mitsunobu reagents (36.6 µmol) in 400 µmol solvent, 40 oC, 5 min. b RCC values are 
average of 2 (n = 2), determined by radio-HPLC. 
Entry a Solvent Trapping (%) RCC (%)b 
1 CH3CN 96% 46 
2 DMSO 89% 18 
3 DMF 82% 13 
4 Toluene 19% 0 
5 Dioxane 7% 0 
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2.3.2 Mitsunobu reagents optimisation 
It has been reported that BEMP traps [11C]CO2 with a similar efficiency to 
DBU.[22] The trapping agents were compared (Table 2.9, Entries 1 and 2) and 
both trapping agents trapped [11C]CO2 efficiently. However, only the reaction 
with DBU produced [11C]compound 1 (Figure 2.2). Reactions were then 
performed using different combinations of Mitsunobu reagents. The highest 
RCCs were observed when tributylphosphine (PBu3) with di-tert-butyl 
azodicarboxylate (DBAD) were used (Table 2.9, Entry 1) and hence, these 




Table 2.9 Optimisation of the Mitsunobu reagents and trapping agent. 
 
 
a Screening conditions: Benzylamine (18.3 µmol), tetrahydroisoquinoline (27.5 µmol), trapping 
reagent (0.8 µmol), Mitsunobu reagents (36.6 µmol) in 400 µmol CH3CN, 40 oC, 5 min. n = 2. b 








Entry a Fixation agent Mitsunobu reagents Trapping (%) RCC (%)b 
1 DBU PBu3 and DBAD 96 46 
2 BEMP PBu3 and DBAD 98 0 
3 DBU PPh3 and DBAD 96 20 
4 DBU PPh3 and DIAD 96 14 








Figure 2.2 Radio-HPLC and UV chromatograms of the crude radiolabelling reaction (Table 2.9, 
Entry 1). The target product is eluted 7:35 minutes. 
 
2.3.3 Temperature and reaction time optimisation 
The temperature dependency of the reaction was examined (Table 2.10). 
Reducing the temperature from 40 oC to 25 oC reduced the RCCs. Loss of 
















performed at 60 oC. Reactions at 50 oC avoided these losses and resulted in 
over a 95 % incorporation of the [11C]CO2 into the target molecules. It was also 
observed that by reducing the reaction time to 1 minute, 96 % RCC was still 
observed (Table 2.10, Entry 6), which laid the foundation for the development of 
this rapid synthesis method for [11C]CO2 incorporation. 
 












a Screening conditions: Benzylamine (18.3 µmol), tetrahydroisoquinoline (27.5 µmol), DBU (0.8 
µmol), Mitsunobu reagents (36.6 µmol) in 400 µmol CH3CN. n = 2. b RCC values are average of 
2 (n = 2), determined by radio-HPLC. 
 
 
2.3.4 Radiolabelling of aliphatic, aromatic and benzylic amines 
The reaction conditions developed using the model reaction were applied to the 
radiolabelling of various ureas using a range of aliphatic, benzylic and aromatic 
amines (Table 2.11). The reactions between a benzylic primary amine and 
hindered secondary amine (Table 2.11, Entry 1) resulted in a high RCC of 95 % 
while the reaction with a less hindered secondary amine produced [11C]ureas to 
lesser degree (Table 2.11, Entry 2). Similarly, high RCCs were observed when 
less reactive compounds such as aniline and derivatives were used instead of 
benzylic amines to form the target radiolabelled molecules at a RCC of over 69 
91 % (Table 2.11). Interestingly, the reaction favours the formation of 
Entry a T/oC Time/min RCC (%) b 
1 40 5 46 
2 25 5 10 
3 60 5 26 
4 50 5 95 
5 50 20 95 
6 50 1 96 
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asymmetrical ureas rather than the symmetrical ureas even though the starting 
materials are available in excess. In the absence of secondary amine, the 11C-
labelled symmetrical urea was formed however, a low RCC of 19 % was 
observed (Table 2.11, Entry 3). 
The effects of functional groups on aromatic amines were also studied. 
Reactions with the electron rich aromatic amines, m-toluidine and p-anisidine, 
resulted in more than 80 % RCC (Table 2.11, Entries 5 and 6). It was also seen 
that poor nucleophiles such as 4-nitroaniline worked efficiently, producing a high 
RCC of 85 % (Table 2.11, entry 7). The reaction favoured the formation of 
asymmetric [11C]ureas despite primary amines being present in excess of 
[11C]CO2. In all of the radiolabelling reactions, unreacted [11C]CO2 accounts for 
> 80 % of the by-product which eluted at the solvent front. Small amount of 



















































a Screening conditions: Primary amine (18.3 µmol), secondary amine (27.5 µmol), DBU (0.8 
µmol) in 300 µmol CH3CN heated at 50 oC for 1 min, Mitsunobu reagents (36.6 µmol) in 100 
µmol CH3CN added and stirred for 1 min. b RCC values are mean ± (standard deviation), n = 3, 
determined by radio-HPLC. 
Entry Product RCC 
1 
 
96 ± 2 
2 
 
74 ± 9 
3 
 
19 ± 15 
4 
 
94 ± 2 
5 
 
69 ± 6 
6 
 
80 ± 10 
7 
 
83 ± 5 
8 
 




The method developed produced high RCCs for asymmetrical ureas. However, 
low RCCs were observed (19 %) when synthesis of [11C]symmetrical ureas was 
attempted. Pharmaceutical compounds that contain symmetrical ureas are not as 
common as compounds that contain asymmetrical ureas. Nevertheless, there are 
many compounds that contain a symmetrical structure such as suramin (used for 
treating sleeping sickness), and as a result, methods to radiolabel such structures 
are of interest. 
[11C]CO2 has been used to radiolabel symmetrical ureas (Scheme 2.16).[14] The 
method produced high RCCs for aromatic and benzylic amines. However, low 
yields were observed for aliphatic molecules.[14] No other methods to radiolabel 
symmetrical ureas with [11C]CO2 have been reported in the literature and 
therefore developing methods to radiolabel symmetrical ureas with [11C]CO2 
directly from the cyclotron is of interest. 
 
2.4 Results and discussion – Symmetrical [11C]ureas 
Model reactions were initially conducted using non-radioactive CO2. The 
synthesis of compound 2 produced highest yields (Scheme 3.22) and was 
subsequently chosen as the model reaction for optimisation with [11C]CO2.  
 





2.4.1 Trapping agent, solvent and base optimisation 
In order to favor the synthesis of symmetrical urea, reactions were initially 
assessed in the absence trapping reagents. Only 5 – 10 % of the produced 
[11C]CO2 was trapped within the reaction vial in the absence of trapping reagent 
and no [11C]radiolabelled target compound was observed (Table 2.12, Entry 1). 
When DBU was used as a trapping agent, [11C]compound 2 was formed in RCC 
of 31 % (Table 2.12, Entry 2). The strong base BEMP did not produce the target 
radiolabelled product (Table 2.12, Entry 3). Furthermore, RCCs were not 
improved when the reaction time was increased from 5 minutes to 15 minutes.  
Optimization of the reaction then focused on screening for appropriate solvents. 
The target [11C]ureas were not formed when DMF, THF and toluene were used 
as the solvent (Table 2.12, Entries 4 - 6) while DMSO (Table 2.12, Entry 7) 
afforded the desired product with a RCC of 24 %. The Mitsunobu reagents were 
prepared separately before being added to the reaction vial. As the reagents were 
insoluble DMSO, the process of transferring the mixture to the reaction vial may 
have been inaccurate, a possible reason for the large variance in product RCC 
(24 ± 12%). The reagent solubility issue was solved by using a mixture of DMSO 
and CH3CN, however, similar RCC were observed. CH3CN produced the highest 
RCC comparing it with other solvents and was therefore selected as the solvent 










Table 2.12 Reaction fixing agent and solvent optimisation. 
Entry a Trapping agent Solvent RCC (%) b 
1 - CH3CN 0 
2 DBU CH3CN 31 ± 8 
3 BEMP CH3CN 0 
4 DBU Toluene 0 
5 DBU THF 0 
6 DBU DMF 0 
7 DBU DMSO 24 ± 12 
a Screening conditions: Amine (18.3 µmol), trapping reagent (0.8 µmol), Mitsunobu reagents 
(36.6 µmol) in 400 µmol solvent at 50 oC, 1 min. b RCC values are mean ± (standard deviation), 
n = 3, determined by radio-HPLC. 
 
2.4.2 Temperature and concentration optimisation  
It was previously stated that reaction temperatures below 50 oC were critical to 
avoid the loss of [11C]CO2 from the reaction vial. When reactions were performed 
at room temperature (Table 2.13, Entry 2), lower RCCs of the [11C]compound 2 
were observed (18 %). Increasing the concentration of the secondary amine did 
not improve the RCC noticeably (Table 2.13, Entry 1). When the concentration of 
the base, DBU, was increased from 0.8 µmol to 3.4 µmol, significant increases in 
RCCs were observed (Table 2.13, Entry 4). Further increasing the base 
concentration to 6.8 µmol reduced the RCC to 15 % (Table 2.13, Entry 5). The 
concentration of DBU was then examined at reduced concentrations (0.4 µmol) 
whereby a significant reduction in [11C]CO2 trapping was observed (12 %). DBU 
is a non-nucleophilic base and its main role in this reaction is to trap [11C]CO2. 
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However, results indicate that the basicity of the molecule has an effect on the 
reaction.  
 
Table 2.13 Reaction optimisation for the synthesis of compound 2. 







1 50 18.3 0.8 31 ± 8 
2 25 18.3 0.8 14 
3 50 36.6 0.8 35 
4 50 18.3 3.4 84 ± 4 
5 50 18.3 8.6 15 
a Screening conditions: Mitsunobu reagents (36.6 µmol) in 400 µmol CH3CN. n = 2. b RCC 
values are mean ± (standard deviation), n = 3, determined by radio-HPLC. 
 
2.4.3 Radiolabelling of various [11C]symmetrical ureas 
The optimised conditions developed for the synthesis of [11C]compound 2 were 
then applied to the radiolabelling of various symmetrical ureas using a range of 
aliphatic and aromatic amines (Table 2.14). High RCCs (> 80 %) of the desired 
[11C]ureas were observed for rigid molecules such as 1-methylpiperazine and 
tetrahydroisoquinoline, presumably due to their low steric hindrance (Table 2.14, 
Entries 1 and 2). Rigid molecules are fixed and no free bond rotations are 
available, this property allows the molecule to be more reactive and hence the 
high conversions. The more flexible benzylic amine produced the target [11C]1,3-
dibenzyl urea but with lower RCC (29 %). Aniline and aromatic amines with 
electron donating and electron withdrawing groups reacted in over 70 % RCC 
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(Table 2.14, Entries 4 - 6). As high RCCs are observed for aromatic amines with 
partially available lone pairs, the reaction is expected to produce similar RCC for 
other weak nucleophiles. 
 
Table 2.14 Radiolabelling various aliphatic, benzylic and aromatic amines with [11C]CO2. 
Entry [11C]Urea RCC (%) 
1 
 
84 ± 4 
2 
 
88 ± 6 
3 
 
29 ± 12 
4 
 
70 ± 2 
5 
 
79 ± 14 
6 
 
72 ± 6 
a Screening conditions: Primary amine (18.3 µmol), DBU (3.4 µmol) in 300 µmol CH3CN 
heated at 50 oC for 1 min, Mitsunobu reagents (36.6 µmol) in 100 µmol CH3CN added 




2.4.4 Reaction mechanism 
The developed synthesis methodology can be divided into two-steps: the first 
step is the trapping of [11C]CO2 by DBU in the presence of an amine, and the 
second step is the Mitsunobu reaction. 
 
2.4.5 Trapping of CO2 
Different CO2 trapping mechanisms have been reported: 
DBU is a non-nucleophilic base due to its steric bulkiness. The steric effect 
prevent large groups form bonding with the base. The reaction mechanism 
proposed by Wilson et al.[15] and Hooker et al.[22] states that DBU is acting as a 
nucleophile and forming a C-N bond with [11C]CO2 (Scheme 2.23). [11C]CO2 is a 
small molecule and therefore, it is possible that it is forming an interaction with 
the base itself.[6, 22] 
 
Scheme 2.23 Plausible method for the trapping [11C]CO2 by DBU.[22] 
It has been reported that when CO2 is bubbled into a reaction vial containing DBU 
and a small amount of water in CH3CN, a bicarbonate salt is formed (Scheme 
2.24). This traps the CO2 within the solution. 
 
Scheme 2.24 Plausible CO2 trapping method by DBU in the presence of H2O.[21-23] 
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2.4.6 Proposed trapping mechanism  
In order to determine the reaction mechanism, the trapping of the [11C]CO2 by 
amines and DBU was investigated. Low [11C]CO2 trapping was observed when 
[11C]CO2 was bubbled into a solution containing DBU and CH3CN. Moreover, 
similar results were observed when [11C]CO2 was bubbled into a solution 
containing an amine and CH3CN. However, high trapping efficiency was 
observed when [11C]CO2 was bubbled into a solution containing amine, DBU and 
CH3CN (> 95 %). These results were in agreement with previously proposed 
methods whereby the base DBU and the amine form an interaction with the 
[11C]CO2 and as a result, a carbamate anion is formed (Scheme 2.25).[6]  
 
Scheme 2.25 Our proposed [11C]CO2 trapping method. 
 
2.4.7 Mitsunobu reaction mechanism 
The Mitsunobu reaction has been extensively studied. When tributylphosphine is 
added to a solution containing diethyl azodicarboxylate and CH3CN, the weak 
azo π bond on the diethyl azodicarboxylate is attacked by the tributylphosphine 
producing a betaine intermediate (Intermediate 1, Scheme 2.26). Oxygen has a 
high affinity for phosphorus and so, the [11C]carbamate anion attacks the 
positively charged phosphorus to form intermediates 3 and 4. The 
oxyphosphonium intermediate (intermediate 4) is then attacked by an amine to 







Scheme 2.26 Synthesis of betaine intermediate. 
Scheme 2.27 The mechanism of Mitsunobu reaction. 
 
2.5 Conclusion 
In conclusion, a method that incorporates [11C]CO2 into aliphatic, aromatic and 
benzylic amines to produce target 11C radiolabelled ureas has been developed. 
Due to the short half-life of 11C, it is attractive to use primary synthons such as 
[11C]CO2 directly for the radiolabelling reaction rather than converting it into 
secondary species such as [11C]CH3I. The method developed in this work uses 
[11C]CO2 directly and rapidly. The synthetic method can be carried out in less 
than 5 minutes from the end of bombardment (excluding purification) and is highly 
efficient. 
Although methods to radiolabel ureas with 11C already exist, they are either 
limited by synthesis complexity or functional group tolerance. The method 
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developed does have some limitations such as the requirement of primary 
amines. However, it is a beneficial addition to the existing arsenal of 11C 
radiolabelling techniques for in vivo molecular imaging.  
Incorporation of stable CO2 into amines using DBU and mitsunobu reagents has 
previously been developed by Petterson et al.[6] In traditional organic chemistry 
synthesis, CO2 is available in excess however, when working at the tracer level, 
the [11C]CO2 is the limiting reagent. Due to the significant stoichiometry changes, 
reaction optimisation is necessary. The reaction with ‘cold’ CO2 is believed to go 
through an isocyanate intermediate which explains why secondary amines 
cannot react with other secondary amines to form ureas. In this work, similar 
results were observed as secondary amines did not react together to form the 
corresponding [11C]asymmetrical urea which suggests that the reaction 
mechanism is the same. 
The novel method to radiolabel ureas produced high RCCs similar to that 
reported in literature (up to 95%) when aliphatic and benzylic amines have been 
used. The reaction produced much higher RCCs for unreactive amines such as 
aniline (up to 91%) compared to the methods described in the literature (6%). 
Increasing the concentration of the base 3-fold favours the formation of 
[11C]symmetrical ureas.  
In summary, a novel one-pot radiolabelling methodology that incorporates 
[11C]CO2 directly into aliphatic, benzylic and aromatic ureas has been developed. 
The synthesis bypasses the need for converting the short-lived [11C]CO2 into 
other reactive radiolabelling species. The broadly applicable 11C-carbonylation 








2.6.1 General  
All purchased chemicals were used without further purification. Chemicals were 
purchased in highest available purity from Sigma-Aldrich and Alfa Aesar and used 
as received (> 99 % purity). All solvents were purchased as anhydrous in highest 
available purity (> 99.8 % purity, water < 50 ppm, extra dry) from Sigma-Aldrich, 
used as received and stored under argon. Reference compounds were either 
purchased from Sigma-Aldrich or synthesised using reported procedures. 
Reactions were carried out under an atmosphere of nitrogen in heat gun dried 
glassware with magnetic stirring. Reactions were monitored using alumina plate 
thin-layer chromatography (Merck, silica gel 60, fluorescence indicator F254, or 
Merck, aluminium oxide neutral, fluorescence indicator F254). Silica gel 
chromatography was performed using 230-400 Mesh (Grade 60) silica gel. The 
mobile phase was a mixture of hexane : ethyl acetate in varying ratios and 
detected by 254 nm UV light. Infra-Red spectra were acquired on a PerkinElmer 
spectrum 100FTIR. 1H-NMR (400 MHz) and 13C-NMR (100 MHz) spectra were 
obtained using a BRUKER DRX 400 MHz spectrometer. Chemical shifts are 
reported in ppm (δ) relative to tetramethylsilane (TMS, d = 0 ppm) and calibrated 
using solvent residual peaks. Data are shown as follows: Chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling 
constant (J, Hz) and integration. Calculated mass was determined using 
PerkinElmer ChemBioDraw Ultra 13.0 program. Mass spectroscopy was 
performed at King’s College London using an Agilent 6520 Accurate-Mass Q-
TOF LC/MS connected to an Agilent 1200 HPLC system with UV detector (254 
nm) and auto-sampler. [11C]CO2 was produced by a Siemens RDS112 cyclotron 
(St Thomas’ Hospital, London, United Kingdom) via the 14N(p,α)11C nuclear 
reaction. Typical irradiation times were 1 minute with a beam current of 10 µA, 
which yielded a [11C]CO2 amount of about 300 MBq at end of bombardment. 
Radiolabelling reactions were performed in a 1.5 mL screw top vial with a “V” 
internal shape. Analytical HPLC was performed on an Agilent 2060 Infinity HPLC 
system with a variable wavelength detector (254 nm was used as default 
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wavelength). An Agilent Eclipse XDB-C18 reverse-phase column (4.6 x 150 mm, 
5 µm) was used at a flow rate of 1 mL/min and H2O/MeOH (HPLC grade solvents 
and with 0.1 % TFA) gradient elution (flow rate: 1 mL/min, 0-2 min: 5% MeOH, 2-
11 min: 5 to 95% MeOH linear gradient, 11-13 min: 90% MeOH, 13-14 min: 90% 
to 5% MeOH linear gradient, and 14-15 min:5% MeOH). The RCC was estimated 
by radio-HPLC and defined as the area under the [11C]urea peak expressed as a 
percentage of the total 11C labelled peak areas observed in the chromatogram. 
Specific radioactivity was calculated from analytical HPLC sample of 25 μL. A 
calibration curve of known mass quantity versus HPLC peak area (254 nm) was 
used to calculate the mass concentration of the 25 μL radiolabelled compound. 
The identity of the radiolabelled compound peak was confirmed by HPLC co-
injection of a nonradioactive reference compound and yielded a single peak. 
 
2.6.2 Synthesis of reference compounds 
Reference compounds can be synthesised using reported procedures.[6] [24] 
 
N-benzyl-3,4-dihydroisoquinoline-2(1H)-carboxamide; CO2 gas was bubbled into 
a solution containing DBU (7 µL, 0.05 mmol) and benzyl amine (51 µL, 0.50 
mmol) in CH3CN (6 mL) for 1 hour at room temperature. Tetrahydroisoquinoline 
(89 µL, 0.70 mmol) was added to the reaction mixture and the vial was flushed 
with N2. In a separate vial, PBu3 (242 µL, 1.00 mmol) was added into a solution 
containing DBAD (226 mg, 1.00 mmol) in CH3CN (2 mL) under nitrogen 
atmosphere. The solution was then added to the mixture dropwise and stirred at 
room temperature for 2 hours under nitrogen. The crude product was 
concentrated and purified by flash chromatography. Colourless solid; 48% yield 
(63 mg); IR 3316.16, 2927.85, 1620.80; 1H NMR (400 MHz, CDCl3) δ 7.06 – 7.55 
(m, 9H), 4.55 (s, 2H), 4.40 (d, J = 5.7, 2H), 3.60 (t, J= 5.6 Hz, 2H), 2.8 (t, J = 6.0, 
2H); 13C NMR (100 MHz, CDCl3) δ 157.5, 139.7, 135.2, 133.6, 128.9, 128.6, 
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128.3, 127.6, 126.9, 126.5, 126.7, 45.8, 45.3, 41.4, 29.4; LCMS calculated for 
C17H18N2O [M+H]+ = 267.1400; found 267.1502. 
 
 
1,3-dibenzylurea; Benzylamine (51 µL, 0.50 mmol) in water was stirred at 0 oC 
for 10 minutes. Carbonyldiimidazole (194 mg, 1.2 mmol) was added and stirred 
at 0 oC for 1 hour. The reaction mixture was then warm up to room temperature 
and monitored by TLC. After complete conversion of amine to 
carbonylimidazolide, benzylamine (51 µL, 0.50 mmol) was added and the mixture 
stirred at room temperature for 3 hours. Reaction mixture was extracted with ethyl 
acetate and the organic later was dried with MgSO4, concentrated, and purified 
by HPLC to give 3 (66 mg, 55 %); IR 3343.80, 2936.59, 1620.79 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.36 – 7.26 (m, 10H), 4.33 (s, 4H); HRMS calculated for 
C15H16N2O [M+H]+ = 241.1335; found 241.1377. 
 
 
Bis(3,4-dihydroquinolin-1(2H)-yl)methanone; Tetrahydroisoquinoline (100 mg, 
0.75 mmol) in CH2Cl2 (3.5 mL) was added to triphosgene (167 mg, 0.56 mmol) 
in CH2Cl2 (0.5 mL) at room temperature. The reaction mixture was stirred for 1 
hour and 1N HCl (3.5 mL) was added. The product was extracted with CH2Cl2 
(2 x 5 mL). The organic layers were dried over MgSO4. The solvent was 
evaporated and the residue was purified by HPLC to give 2 (32 mg, 29%); IR 
3320.53, 2918.23, 1625.84 cm-1; 1H NMR (400 MHz, CD3OD) δ 7.15 (m, 6H), 
7.11 (m, 2H), 4.49 (s, 4H), 3.57 (m, 4H), 2.95 (m, 4H); 13C NMR (100 MHz, 
CD3OD) δ 29.5, 45.8, 49.9, 127.3, 127.9, 128.8, 129.7, 133.8, 135.8, 165.8; 




Bis(4-methylpiperazin-1-yl)methanone; Diisopropylethylamine (194 mg, 1.50 
mmol) was added to mixture of 1-methylpiperazine (50 mg, 0.50 mmol), 4-
methylpiperazin-l-ylcarbonyl chloride (122 mg, 0.75 mmol) in dichloromethane 
(20 mL) and the resultant mixture was stirred at room temperature for 1 hour. The 
mixture was concentrated and recrystallized from ethanol to give 1 (30 mg, 27 
%); 1H NMR (400 MHz, CDCl3) δ 3.59 (m, 8H), 2.56 (m, 8H), 2.9 (s, 6H); 13C NMR 
(100 MHz, CD3OD) δ 163.65, 54.03, 45.04, 43.79; HRMS calculated for 
C11H22N4O [M+H]+ = 227.1866; found 227.1803.  
 
2.6.3 [11C]CO2 Trapping  
The following set-up was chosen in order to trap and measure the radioactivity, 





Figure 2.3 Reaction set-up. 
DBU was added into a reaction vial containing an amine in CH3CN. [11C]CO2 with 
a stream of helium gas at a flow rate of 1.4 mL/min post target depressurisation 
was bubbled directly into a reaction mixture. Helium and any un-trapped gases 
are transferred to a second vial containing concentrated NaOH solution (to 
measure untrapped [11C]CO2) prior to escaping to the waste bag. 
 
[11C]CO2 / He 
Amine + DBU 




      11C in the reaction vail               
(11C in the reaction vial + 11C in the NaOH solution)  
 
2.6.4 General radiolabelling procedure asymmetrical ureas 
[11C]CO2 from the cyclotron target was bubbled in a stream of helium gas at a 
flow rate of 1.4 mL/min post target depressurisation directly into a reaction vial 
containing an amine (18.3 µmol), secondary amine (27.5 µmol) and DBU (0.13 
µL, 0.9 µmol) in CH3CN (300 µL). [11C]CO2 from the cyclotron was bubbled in the 
reaction mixture and the resulting solution was stirred, and heated at 50 oC for 1 
minute. In a separate vial, tributylphosphine (9 µL, 36.6 µmol) was added to a 
solution containing di-tert-butyl azodicarboxylate (8 mg, 36.6 µmol) in CH3CN 
(100 µL) under argon at room temperature. The resulting solution was transferred 
into the reaction mixture and stirred for one minute at 50 oC. The reaction was 
quenching it with water, the crude product was analysed by radio-HPLC. 
 
2.6.5 General radiolabelling procedure symmetrical ureas 
[11C]CO2 from the cyclotron target was bubbled in a stream of helium gas at a 
flow rate of 1.4 mL/min post target depressurisation directly into a reaction vial 
containing an amine (18.3 µmol) and DBU (0.13 µL, 0.9 µmol) in CH3CN (300 
µL). [11C]CO2 from the cyclotron was bubbled in the reaction mixture and the 
resulting solution was stirred, and heated at 50 oC for 1 minute. In a separate vial, 
tributylphosphine (9 µL, 36.6 µmol) was added to a solution containing di-tert-
butyl azodicarboxylate (8 mg, 36.6 µmol) in CH3CN (100 µL) under argon at room 
temperature. The resulting solution was transferred into the reaction mixture and 
stirred for one minute at 50 oC. The reaction was quenching it with water, the 
crude product was analysed by radio-HPLC. 
The specific activity of the products was in the range of 20-40 GBq/μmol, similar 
in magnitude to other 11C-labelled compounds produced at this laboratory. 
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3 Chapter 3 
 Introduction 
Carbamates are common functional groups in biomolecules due to their stability 
in vivo, while carbonates are less common as they are less stable.[1] 
Nevertheless, carbamates and carbonates are found in various biologically active 
molecules (Figure 3.1) such as parabolan (an antiretroviral drug), zopiclone (a 
hypnotic agent) and physostigmine (a cholinesterase inhibitor).[2]  
 
Figure 3.1 The chemical structure of zopiclone, physostigmine and parabolan. 
The reaction between amines and chloroformate is one of the simplest reactions 
used for the synthesis of carbonates and carbamates (Scheme 3.1).[3] 
 
 The synthesis of carbamates using chloroformate.[3] 
There are many literature reviews describing the synthesis of carbamates and 
carbonates.[4] Some of the main synthetic strategies include the use of 
isocyanates, CO and CO2.  
 
3.1.1 Synthesis of carbamates via isocyanates 
One of the most commonly used synthetic methods for the synthesis of 
carbamates is via isocyanates.[5] Isocyanates are obtained through the reaction 
of amines with phosgene (COCl2); the addition of an alcohol forms carbamates 




 The synthesis of carbamates via an isocyanate intermediate. 
Isocyanates can also be synthesised using the Hoffmann rearrangement[7] 
(Scheme 3.3), Curtius rearrangement[8] (Scheme 3.4) or Lossen rearrangement[9] 
(Scheme 3.5), and subsequently converted into the carbamate. 
 
 The synthesis of carbamates via the Hoffmann rearrangement.[7] 
 
 The synthesis of carbamates via the Curtius rearrangement.[8] 
 
 The synthesis of carbamates via the Lossen rearrangement.[9] 
 
3.1.2 Synthesis of carbamates from carbon monoxide 
Carbon monoxide (CO) has been used for the synthesis of carbamates and 
carbonates. High pressures, temperatures and a catalyst are generally required 
for reactions with CO.[10]  
Leung et al.[11] developed one of the first methods to incorporate CO into 
carbamates. Different catalysts such as cobalt (Co), rhodium (Rh), palladium (Pd) 
and copper (Cu) macrocyclic compounds were screened during reaction 
optimisation. The highest yields were obtained when Co or Rh was used as a 
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catalyst, NaI was used as a co-catalyst and a pressure of 6.9 MPa was used 
(Scheme 3.6). 
 
 Cobalt-catalysed carbamate synthesis.[11] 
High yields were obtained when aromatic amines (aniline) and tertiary amines 
(tert-butyl amine) were used. However, due to the limited number of examples 
provided, the scope of the reaction is not clear. 
Reactions with CO are expected to require high pressures and temperatures. 
However, Ren and Jiao[12] developed an attractive novel method to incorporate 
CO into carbamates at ambient pressure. Ligand-free palladium (ll) chloride 
(PdCl2) salt was used as a catalyst and CO was introduced into the system via a 
balloon (Scheme 3.7).  
 
 Palladium-catalysed carbamate synthesis.[12] 
During reaction optimisation, high yields were observed when polar solvents such 
as dimethylacetamide (DMA) were used, while no product or only trace amounts 
of product were detected when non-polar solvents were used. Interestingly, 
reduced yields (35 %) were observed when the ligand triphenylphosphine (PPh3) 
was added to the reaction mixture. The scope of the reaction was investigated 
using different alcohols and azides (Table 3.1). Aryl azides with electron donating 
and electron withdrawing groups produced the target product at yields of over 80 
%. High yields were also observed when primary and secondary azides were 
used. However, low yields of 14 % were observed when tertiary azides were 


















When the azide and PdCl2 were added to the reaction mixture, an intermediate 
(Complex A) was formed with the release of N2 (Scheme 3.8). CO was then 
inserted into the Pd Complex A to form the 3-membered ring intermediate, 
Complex B. A reductive elimination process then took place to form the 
isocyanate and the Pd-catalyst was subsequently regenerated. When alcohol 
was added to the mixture, nucleophilic addition took place to form the 
corresponding carbamate. 






















 The proposed reaction mechanism for the Pd-mediated synthesis of Pd.[12] 
 
3.1.3 Synthesis of carbamates from carbon dioxide 
CO2 has been used extensively for the synthesis of carbamates. Many methods 
for the synthesis of carbamate derivatives such as oxazolidinone and 
polyurethane have been developed. 
Paz et al.[13] used phosphorylating agents such as diphenyl phosphorochloridate 
(DPPCl) along with 1,1-amino alcohol and CO2 to form cyclic carbamates with 
high yields. Other dehydrogenation reagents such as thionyl chloride (SOCl2) and 
methanesulfonyl chloride (MsCl) can also be used. Due to the reagents reactivity, 
the reaction mixture has to be cooled to - 40 oC in order to obtain efficient yields. 
When the CO2 is trapped within the solution, a carbamate anion is formed 
followed by two possible intermediates (Scheme 3.9). The intermediates 
subsequently cyclise to form the target compound. 
 




Another strategy for the synthesis of carbamates via CO2 was developed by Miller 
and Nguyen.[14] (Salen)chromium(III)/DMAP was found to be an ideal catalyst for 
inserting CO2 into aziridines to form oxazolidinones. The reaction scope was 
examined with compounds containing various N-substituted and 1,2-disubstituted 
aziridines (Table 3.2). The reaction is efficient as it produces high yields for all of 
the assessed compounds including compounds with bulky N-substituted groups. 
The rates of reaction for different compounds were also explored and as 
expected, reactions with sterically hindered groups had low rates of reaction. 
Bulky azides coordinate poorly to the Cr centre, slowing their conversion to 
oxazolidinones. 
 































3.1.4 Synthesis of carbonates  
Carbonates are generally synthesised using either carbonochloridate or CO2. Kim 
and Jang[3] showed that carbonochloridate can be used for the synthesis of 
carbamates when it is added to alcohols and indium (Scheme 3.10). 
 
 Indium-catalysed carbonate synthesis.[3] 
High yields of over 70 % were observed for aliphatic and aromatic alcohols. High 
yields were also observed for compounds with electron withdrawing groups such 
as nitrophenol (72 %). However, low yields were observed for satirically hindered 
tertiary alcohols such as tetra-butyl alcohol (41 %). 
Another method for the synthesis of carbonates is via mesyl carbonates.[15] Mesyl 
compounds are frequently used to make hydroxyl groups a good leaving groups, 
due to theirs low costs and ease of handling (Scheme 3.11).  
 
 The synthesis of carbamates via mesyl carbonates.[15] 
The reaction is useful as it produces the target compound but in low yields (Table 
3.3). The expected product was not observed when bulky alcohols such as 
isobutyl alcohol were used (Table 3.3, Entry 4). 


















Calo et al.[16] developed a method for the synthesis of cyclic carbonates by 
coupling CO2 and epoxides (Scheme 3.12). Many similar methods are available 
[17] however; this method is interesting due to the simplicity of the reaction and 
the high yields of the product produced. The product is formed when epoxides 
are dissolved in tetrabutylammonium bromide, in the presence of CO2.  
 
 The reaction between epoxides and CO2.[16] 
High yields are observed when aliphatic, aromatic and benzylic amine R-groups 
are used (Table 3.4). 








The reaction uses CO2 which is a readily available reagent, and is performed 
under atmospheric pressure which makes it attractive. The translation of this 
















3.1.5 Synthesis of carbamates and carbonates via CO2 
Salvatore et al.[18] developed a method to incorporate CO2 into carbamates and 
carbonates (Scheme 3.13) using caesium carbonate (Cs2CO3) as a base in the 
presence of tetrabutylammonium iodide (TBAI).  
 
 The developed method for the synthesis of carbamates and carbonates.[18] 
Caesium (Cs) plays an important role in the reaction as it is involved in charge 
stabilisation by forming a weak conjugate with the alkoxides generated in situ 
(Scheme 3.14). 
 
 The trapping of CO2 by amine/alcohol and Cs2CO3.[18] 
TBAI was found to be an essential additive. In absence of TBAI, N-alkylation is 
observed (Scheme 3.15) rather than the generation of carbamates and 
carbonates.  
 
 The reaction in the absence of TBAI.[18] 
The methodology was used for the synthesis of several carbamate and carbonate 
compounds. The reaction produced high yields for both chemical structures when 

















The reaction is one of the few methods available that has been shown to work to 
synthesise both carbonates and carbonates. Translating the reaction into a 
radioactive synthesis (using [11C]CO2) would enhance the portfolio of available 
molecules that can be radiolabeled with 11C. 
Since carbamates are common in biologically active molecules, the development 
of methods to radiolabel the functional group with PET radionuclide is of 
considerable interest. The structure has been radiolabelled previously using 
Grignard reactions as well as [11C]COCl2, [11C]CO and [11C]CO2. 
 
3.1.6 Synthesis of [11C]carbonates and [11C]carbamates via the Grignard 
reaction 
The Grignard reaction is one of the most well studied reactions used for C – C 
bond formation. When [11C]CO2 is treated with Grignard reagents, 
[11C]carboxylmagnesium halide is formed. With the addition of phthaloyl 
dichloride, the corresponding acid halide is formed (Scheme 3.16).  
 



















 Synthesis of acid halides using the Grignard reaction.[19] 
When Bu4NN3 was added to the acid halide, the corresponding isocyanate 
compound was formed (Scheme 3.17). 
 
 Synthesis of [11C]isocynates from [11C]acid halide.[19] 
One of the main disadvantages of using the Grignard reaction is the high 
reactivity of the reagents. The Grignard reagents readily absorb CO2 from the 
atmosphere and are moisture-sensitive. Therefore, they have to be freshly 
prepared under inert atmosphere to obtain high specific activity. 
This reaction has not been used for the radiolabelling of biomolecules that contain 
carbonates, however it has been used for the radiolabelling of carbamates such 
as heptylphysostigmine and physostigmine.[20] 
Physostigmine is a reversible cholinesterase inhibitor that is found in the Calabar 
bean.[21] The reaction is a multi-step synthesis (Scheme 3.18) and includes the 
trapping of [11C]CO2, the Grignard reaction, synthesis of [11C]acyl halide, 
synthesis of [11C]isocyanate and finally the formation of the [11C]physostigmine 
(Table 3.6).[20] The overall reaction time, including formulation, was approximately 
60 minutes (Table 3.6) and the RCY 14 ± 3 % (decay corrected).  
 






Table 3.6 Overview of the synthesis of [11C]physostigmine.[20] 
 Radioactivity 
(GBq) 
RCY % (decay 
corrected) 
Time (min) EOB 55.5 100 
0 to 5 [11C]CO2 46 98 
5 to 20 [11C]CH3OCl 15 52 
20 to 37 [11C]CONCH3 3.7 23.5 
37 to 52 [11C]physostigmine 1.42 15.5 
52 to 57 Formulation 1.19 14.5 
 
The radiolabelling reaction is useful and produces the target compound. 
However, multi-step radiosynthesis and potential for isotopic dilution limits the 
usability of the Grignard reaction. 
 
3.1.7 Synthesis of [11C]carbamates via [11C]phosgenes 
[11C]COCl2, produced from [11C]CO2, is one of the most useful synthons used for 
radiolabelling with 11C. Various compounds have been radiolabelled using the 
synthon due to the reaction being rapid and efficient.  
Lemoucheux et al.[22] developed a method to radiolabel carbamates with 
[11C]COCl2. The reaction was developed for the radiosynthesis of [11C]urea 
however, the authors demonstrated that the reaction can also be used for the 
radiolabelling of carbamates. Tetrahydroisoquinoline was chosen as the structure 
is frequently encountered in biomolecules, and the presence of an aromatic ring 
enables the compound to be UV active.  
[11C]carbamoyl chloride was initially synthesised by reacting an amine with 
[11C]COCl2 and sodium ethanolate (Scheme 3.19). A RCY of over 94 % was 





 The synthesis of a [11C]carbamate via [11C]carbamoyl chloride.[22] 
Although the reaction was rapid and produced the target 11C labelled carbamate 
efficiently, the reaction was limited by the synthesis of [11C]COCl2. Specialised 
equipment is required for its synthesis. The [11C]COCl2 is obtained from a multi-
step reaction which affects the RCY as 11C has a fairly short half-life.  
 
3.1.8 Synthesis of [11C]carbamates via [11C]carbon monoxide 
As previously stated in chapter 2, one of the main challenges encountered when 
radiolabelling with [11C]CO is the low solubility in organic reagents. The reaction 
with [11C]CO usually requires high pressure, high temperature and a catalyst. 
Nevertheless, there are methods available to radiolabel carbamates with 
[11C]CO. 
Doi et al.[23] developed one of the first methods to radiolabel carbamates with the 
[11C]CO (Scheme 3.20). The reaction requires high pressure (35 MPa), high 
temperature (120 oC to 150 oC) and Rh complex ([RhCl(cod)]2 /3 dppe).  
 
 Rhodium-mediated [11C]carbamate synthesis.[23] 
Different reagent concentrations were explored (Table 3.7) and high trapping 
efficiencies with good RCYs were observed when the lithium ethoxide (EtOLi) 







Table 3.7 Synthesis of [11C]ethyl phenylcarbamate by Rh-promoted carbonylation 
Entry Rh Complex Additive [11C]CO trapping 
(%) 
RCYa (%) 
1 RhCl(PPh3)3 - 27 34 
2 [RhCl(cod)]2/2dppe - 70 25 
3 [RhCl(cod)]2/3dppe - 74 30 
4 [RhCl(cod)]2/3dppe LiBr 81 40 
5 [RhCl(cod)]2/3dppe EtOLi 90 76 
 
a Determined by radio-HPLC.[23] 
Similar to many other [11C]CO radiolabelling methodologies, the reaction is 
believed to proceed via an isocyanate intermediate (Scheme 3.21). 
 
 The proposed Rhodium-mediated reaction mechanism.[23] 
The radiolabelling strategy used [11C]CO to radiolabel carbamates. High RCYs 
(> 70 %) were obtained however, high pressure and temperature was required, 
limiting the feasibility of the reaction.  
Another method to radiolabel carbamates using [11C]CO was developed by 
Kihlberg et al.[24] Sufficient trapping is observed when [11C]CO is bubbled into a 
solution containing selenium, an amine and an alcohol in DMSO (50 - 95 %). A 
pressure of 0.3 – 0.4 MPa was required to obtain the target product, achieved 
using a microautoclave.  
The reaction is believed to proceed by a similar mechanism to that with non-
radioactive CO. Selenium (Se) traps the [11C]CO within the solution by forming 
carbonylselenide. In the presence of an amine, the carbonylselenide reacts with 





 The formation of the carbamoselenoate intermediate.[24] 
When the amine added is a primary amine, the reaction is believed to form an 
isocyanate intermediate (Scheme 3.23), while secondary amines proceed via 
bis(carbamoyl) diselenides (Scheme 3.24). 
 
 The synthesis of [11C]isocyanate with primary amine.[24] 
 
 The synthesis [11C]bis(carbamoyl) diselenides with secondary amine.[24] 
 
3.1.9 Synthesis of [11C]carbamates via [11C]carbon dioxide 
[11C]CO2 is the most commonly used synthon for the radiolabelling of carbonates. 
Hooker et al.[25] developed the first one-pot synthesis to directly incorporate 
[11C]CO2 into a carbamate (Scheme 3.25). 
 
 The synthesis of [11C]carbamate via [11C]CO2.[25] 
The reaction involved the use of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) as a 
trapping agent (Scheme 3.26). The authors propose that the [11C]CO2 is trapped 
by DBU and the resulting complex (Intermediate A) reacts with alkyl chloride to 
form a second complex (Intermediate B). The second complex then reacts with 




 The proposed mechanism for the synthesis of [11C]carbonate.[25] 
Different reaction conditions were used during the reaction optimisation process. 
The RCY was low when the reaction was carried out at room temperature. High 
RCYs were obtained with higher temperatures until a plateau was reached (75 
oC, Table 3.8, Entry 2); after which the yield starts to decline (Table 3.8, Entry 3). 
The best results were obtained when the reaction was performed in DMF, at 75 
oC and for 10 minutes. 
Table 3.8 The effect of temperature on the radiosynthesis of [11C]carbamates. a Determined by 
radio-HPLC.[25] 
Entry T (oC) RCYa (%) 
1 25 17 
2 75 85 
3 100 75 
 
Primary and secondary benzylic amines produced the target [11C]carbamate with 
RCYs of over 60 % (Table 3.9, Entries 1 and 2). When aliphatic halides were 
used, the RCYs were reduced to less than 10 % (Table 3.9, Entries 3 and 6) and 
when aromatic amines (i.e. aniline) were used in the reaction, poor RCYs were 






















a Determined by radio-HPLC. 
The reaction was rapid and attractive as it produced the [11C]carbamate using 
[11C]CO2 directly from the cyclotron. However, the strategy was limited by the low 
RCYs observed for aromatic amines. 
Wilson et al.[26] also developed a one-pot synthesis to incorporate [11C]CO2 into 
carbamate compounds using 2-tert-Butylimino-2-diethylamino-1,3-
dimethylperhydro-1,3,2 diazaphosphorine (BEMP). 
 
Figure 3.2 The chemical structure of DBU and BEMP.[26] 





















The reaction mechanism is believed to proceed via [11C]isocyanate intermediates 
(Scheme 3.27), which react with amines to give carbamate compound. 
 
 The proposed mechanism of [11C]urea synthesis via isocyanate.[26] 
A large excess of POCl3 (57 µmol) was found to favour the formation of 
isocyanate and when methanol was added to the reaction mixture, the target 
carbamate product was produced (Scheme 3.28). Reducing the POCl3 (5.4 µmol) 
encouraged the formation of [11C]symmetrical urea as the major product. 
 
 The effect of POCl2 concentration on the product.[26] 
A notable feature of this method is that the overall synthesis time was under five 
minutes. The radiolabelling procedure used cyclotron-produced [11C]CO2 to 
radiolabel aliphatic and benzylic amines to form [11C]carbamates. 
The developed reaction was used by the group for radiolabelling various 
pharmaceuticals including URB694, SL25.1188, and metergoline.[27]  
URB694 is a second generation phenyl carbamate fatty acid amide hydrolase 
inhibitor.[28] The method was used to radiolabel the compound to give an overall 
RCY of 0.7 ± 0.3 % based on the starting [11C]CO2 (uncorrected for decay) and a 





 The radiolabelling of URB694 with [11C]CO2.[27b] 
The method has also been used to radiolabel SL25.1188, a promising 
monoamine oxidase B tracer. The tracer has previously been radiolabelled using 
[11C]COCl2 which limited its use due to specialised equipment and technical 
expertise being required.[27a] The compound was radiolabelled with [11C]CO2 with 
an overall radiochemical yield of 11.5 ± 0.9% based on the starting [11C]CO2 
(uncorrected for decay), a radiochemical purity of > 99 % with a total synthesis 
time of 30 minutes and specific activity of 37.0 ± 1.7 GBq/µmol (Scheme 3.30).[29]  
 
 The radiosynthesis of [11C]SL25.1188 with [11C]CO2.[29] 
 
Another method to radiolabel carbamates with [11C]CO2 has been described by 
Wilson et al.[30] Initially, the authors compared the trapping efficiency of [11C]CO2 
by DBU and BEMP. Although both agents trapped 95 % of the [11C]CO2, the 
reaction using BEMP produced the target product with higher RCY (93 %) 







Table 3.10 The effect of DBU and BEMP on the reaction RCY. [30] 
Entry Trapping agent RCYa (%) 
1 DBU 79 
2 BEMP 93 
 
a Determined by radio-HPLC 
Two possible mechanisms were proposed for trapping the [11C]CO2. The first 
method involved the trapping reagent interacting with the [11C]CO2 to form a 
zwitterion intermediate as shown in scheme 3.31. The intermediate is methylated 
by the DMS followed by nucleophilic substitution with the amine. 
 
 The first proposed mechanism by Wilson et al.[30] 
In the second proposed mechanism, nucleophilic substitution with the amine 
takes place before methylation with DMS (Scheme 3.32). 
 
 The second proposed mechanism by Wilson et al.[30] 
The method is used for the radiolabelling of GR 103545 (a selective kappa opioid 
receptor agonist).[30] The compound was radiolabelled with [11C]CO2 with an 
overall RCY of 13 % based on the starting [11C]CO2 (uncorrected for decay) and 




 The radiosynthesis of [11C]GR 103545.[30] 
 
3.1.10 Synthesis of [11C]carbonates 
There are no methods available to radiolabel carbonates with carbon-11 (11C). 
This could be due to carbonates being less common compared to other structures 
such as carbamates. Carbonates are metabolised by proteins in the blood and 
as a result, only a limited amount of the tracer reaches the target receptor. 
However, radiolabelling carbonates would enable the studies of drug-protein 
interactions and metabolite studies. Therefore, strategies to radiolabel 
carbonates as well as carbamates with 11C is of interest. 
 
3.1.11 Summary 
There are numerous compounds that contain carbamates and carbonates and 
as such, various methods have been developed for their synthesis. The 
carbamate structure has been radiolabelled with [11C]CO and [11C]CCl4. Although 
the radiolabelling methods are useful and produce the target compound, they are 
limited by the specialised equipment required to perform the radiolabelling 
reactions. More recently, two new methods to radiolabel carbamates with 
[11C]CO2 directly from the cyclotron have been developed. The methods are 
efficient and have been used for the radiolabelling of SL25.1188 (Scheme 3.30) 
and GR 103545 (Scheme 3.33).  
Although carbamates have a similar structure to carbonates, there are no 
methods available to radiolabel carbonates with 11C and as PET imaging is 
becoming more widely available in clinical and research environments, the 
demand for more radiolabeling techniques is increasing. 
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The aim of this project was to develop a one-pot radiolabelling methodology that 
incorporates [11C]CO2 directly into alcohols/amines for the synthesis of 
[11C]carbonates and [11C]carbamates.  
 
 Results and discussion 
The reaction for the radiosynthesis of [11C]benzyl isopropyl carbonate (compound 
1) was selected as a model reaction for optimisation due to high yields observed 
in non-radioactive synthesis. 
 
 Synthesis of reference compound. 
3.2.1 Base optimisation 
The initial challenge that is usually encountered when developing a novel 
[11C]CO2 radiolabelling strategy is the trapping of the radioactive gas within the 
reaction mixture. The trapping efficiencies of different caesium (Cs) bases in DMF 
were explored (Table 3.11). DMF was reported to work best for the synthesis of 
carbamates and carbonates when using non-radioactive CO2 and therefore, it 
was selected as the solvent of choice.[18] 
When Cs2SO4 and CsI were used as the trapping reagent, a minute amount of 
11C was detected within the solution (Table 3.11, Entries 1 and 2). The strongest 
bases screened, Cs2CO3 and CsOH, trapped the cyclotron-produced [11C]CO2 
very effectively (Table 3.11, Entries 4 and 5) while CsF trapped to a lesser degree 
(33 %). These results indicate that the basicity of the Cs compound has an effect 
on the trapping efficiency. 
Cs bases have low solubility in DMF and as a result, the reaction mixture is 
heterogeneous. Vigorous stirring of the mixture was essential for the reaction to 
proceed. The low solubility of Cs compounds can be explained by the size of the 
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ion. Large ions such as Cs have a low degree of solvation in a reaction medium. 
As the Cs compounds are the trapping agent, it was essential to use flat-end 
needles and a low carrier gas flow rate to obtain sufficient [11C]CO2 trapping. 
The radiolabelling reactions with Cs2CO3 produced the target radiolabelled 
compound with a moderate RCC of 24 % (Table 3.11, Entry 4) while CsI produced 
the target compound at a RCC of 5 % (Table 3.11, Entry 2). Although CsOH 
trapped the radioactive isotope efficiently (> 98 %), the reaction did not produce 
the target compound (Table 3.11, Entry 5). Similarly, the radiolabeled product 
was not observed when Cs2SO4 and CsF were used.[18] The RCCs was estimated 
by radio-HPLC and defined as the area under the target 11C-labelled target 
product peak expressed as a percentage of the total 11C labelled peak areas 
observed in the chromatogram 
Cs2CO3 was then compared with potassium carbonate and calcium carbonate 
(Table 3.11, Entries 6 and 7). The trapping efficiencies were extremely low for 
both reagents and the target product was not produced. Similar results have been 
reported in the literature when non-radioactive CO2 is used.[18] These 
observations indicate that Cs plays a role in trapping the radioactive [11C]CO2 and 
the synthesis of target molecule. Cs has a large cationic radius, a low charge 
density and is highly polarizable. This enables Cs to be “stripped” when added to 
an aprotic solvent such as DMF which enables it to form a weak conjugation with 











Table 3.11 The base optimisation reactions. 
Entrya Base Trapping (%) RCCb (%) 
1 Cs2SO4 1.5 0 
2 CsI 4.3 5 
3 CsF 33.5 0 
4 Cs2CO3 95.2 24 
5 CsOH 98.7 0 
6 K2CO3 10 0 
7 CaCO3 0 0 
 
a Screening conditions: isopropyl alcohol (22 µmol), TBAI (66 µmol), base (66 µmol) in 400 µmol 
DMF. Benzyl chloride (66 µmol) 25 oC, 10 min. b RCC values are average of 2 (n = 2), 
determined by radio-HPLC. 
 
After discovering Cs2CO3 was the best base for the reaction, experiments were 
then evaluated in different solvents, temperatures and reaction times (Table 
3.12).  
 
3.2.2 Solvent, temperature and time optimisation 
DMF, CH3CN and DMSO were selected as solvents due to their aprotic properties 
which enable them to polarize Cs compounds. CH3CN and DMSO trapped 
[11C]CO2 but to a lesser extent than DMF (20 % and 65 % respectively). Only 
reactions conducted with DMF as the solvent produced the target radiolabeled 
product (Table 3.12, Entry 1) and therefore, DMF was selected as the solvent of 
choice for subsequent reactions.  
The reaction dependency on temperature was then examined. At room 
temperature, 24 % RCC was observed however, when the temperature was 
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increased to 65 oC, the RCC increased to 33 % (Table 3.12, Entry 5). Increasing 
the reaction temperature further to 100 oC promoted the product formation and 
resulted in a RCC of 82 %.  
A short reaction time is beneficial when radiolabelling with 11C. Reducing the 
reaction time from 10 minutes to 5 minutes reduced the RCC slightly (Table 3.12, 
Entries 6 and 7). Doubling the reaction time to 20 minutes resulted in similar 
RCCs to that obtained with 10 minutes reaction time.  
Reactions conducted at 100 oC for 10 minutes produced the best results, 
however, high reagent concentrations were used. The use of lower regent 
concentrations is advantageous, especially for radiolabelling complexes and 
precious precursors. The next experiments explored the possibilities of reducing 
the reagent concentrations.  
 
Table 3.12 The solvent, time and temperature optimisation reactions. 
Entrya Solvent T (oC) Time (min) RCCb (%) 
1 DMF 25 10 24 
2 CH3CN 25 10 0 
3 DMSO 25 10 0 
5 DMF 65 10 33 
6 DMF 100 10 81 
7 DMF 100 5 77 
8 DMF 100 20 81 
 
a Screening conditions: isopropyl alcohol (22 µmol), TBAI (66 µmol), Cs2CO3 (66 µmol) in 400 





3.2.3 Concentration optimisation  
The results in Table 3.13 indicated that reducing the concentration of the 
organohalide and TBAI has a significant effect on the RCC (Table 3.13, Entries 
2 and 3). TBAI was found to be essential for the reaction to proceed as the target 
product was not observed in its absence (Table 3.13, Entry 4). Nucleophilic 
addition of alcohols into organohalides was favoured in the absence of TBAI 
when the reaction was performed with non-radioactive CO2 which reduces the 
availability of the reagents for [11C]CO2 incorporation. 
Reducing the concentration of Cs2CO3 reduced the trapping efficiency to 5 – 15 
% and the RCC to 4% (Table 3.13, Entry 5). 
 
Table 3.13 The concentration (equivalence) optimisation reactions. 
Entry ROH R-Cl Cs2CO3 TBAI RCCb % 
1a 1 3 3 3 82 
2 0.3 1 1 1 0 
3 1 1 1 1 0 
4 1 3 3 - 0 
5 3 3 1 3 4 
 
a Reaction conditions: alcohol (1.65 µL, 22 µmol), TBAI (24 mg, 66 µmol), Cs2CO3 (21 mg, 66 
µmol) in 400 µmol DMF. Benzyl chloride (7.5 µL, 66 µmol), 100 oC, 10 min. n = 3. RCC values 
are average of 2 (n = 2), determined by radio-HPLC.  
 
After examining the reaction with different bases, concentrations, solvents and 
temperatures, best results were obtained when Cs2CO3 and DMF were used at 
100 oC.  
It has been shown that in some cases, similar reaction conditions can be used 
for the synthesis of carbamates and carbonates when working with non-
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radioactive CO2.[18] Our optimized reaction conditions for the radiosynthesis of 
[11C]carbonates were therefore tested for the radiolabelling of [11C]carbamates. 
RCCs of 90% were observed when tetrahydroisoquinoline and benzyl chloride 
were used for the radiosynthesis of compound 2 (Scheme 3.35). This suggested 
that the developed method could be used to radiolabel both carbamates and 
carbonates. 
 
 The radiolabelling of carbamate with [11C]CO2. Reaction conditions: Amine 
(1.65 µL, 22 µmol), TBAI (24 mg, 66 µmol), Cs2CO3 (21 mg, 66 µmol) in 400 µmol DMF. 
Benzyl chloride (7.5 µL, 66 µmol), 100 oC, 10 min. 
 
3.2.4 HPLC analysis 
When the developed method was used for radiolabelling, the target product was 
the main peak observed on the radio-HPLC chromatogram (Figure 3.3, A). A 
small radioactive peak was observed around the solvent front which could be 
[11C]carbonate or unreacted [11C]CO2 interacting with Cs.  
Although high conversions were observed for both [11C]carbonates and 
[11C]carbamates on the radio-HPLC chromatogram, the UV-HPLC chromatogram 
showed a major mass peak for the reference compound suggesting a low specific 
activity (Figure 3.3). The typical specific activity of 11C-labelled compounds 
produced in the laboratory is in the range of 30-50 GBq/µmol at the EOB. The 
specific activity produced by the Cs2CO3-mediated reaction was in the range of 






    
    
 
Figure 3.3 The crude radio-HPLC of compound 2. [A] Radioactivity (counts per sec.). [B] UV 
absorption at 254 nm.  
 
3.2.5 Reaction mechanism  
The results indicated that Cs2CO3 and TBAI were essential for sufficient [11C]CO2 
trapping and forming the target product. Similar results were observed when the 
reaction was performed using non-radioactive CO2. It was therefore reasonable 
to presume that the radiolabelling reaction followed a similar mechanism to that 












3.2.6 Synthesis of [11C]carbamates  
A nucleophilic attack from the amine lone pair on the [11C]CO2 forms an 
ammonium salt. The ammonium salt is deprotonated by the Cs2CO3 base to form 
a Cs carbamate salt and Cs bicarbonate (Scheme 3.36). 
 
 The synthesis of Cs carbamate salt. 
Organochlorides interact with TBAI to form organoiodide (Scheme 3.37).  
 
 The synthesis of organoiodide. 
 
The organoiodide reacts with the Cs carbamate salt to form the target product 
(Scheme 3.38). 
 
 Synthesis of [11C]carbamates. 
 
3.2.7 Synthesis of [11C]carbonates 
The mechanism for the synthesis of [11C]carbamates is expected to be similar to 
that of [11C]carbamates (Scheme 3.39). 
 






A novel radiolabelling methodology for the radiosynthesis of [11C]carbamates and 
[11C]carbonates has been developed. The method uses [11C]CO2 directly from 
the cyclotron and gives a high RCCs in a short reaction time. The strategy 
enables the radiolabelling of carbonates which were previously inaccessible for 
11C radiolabelling. This reaction is therefore a useful addition to the arsenal of 
methodologies available for 11C radiolabelling.  
Due to the presence of carbonate (from Cs2CO3), the reaction results in a low 
specific activity. Although this is undesirable for receptor or enzyme imaging, the 
method can be used for other purposes including the study of the biodistribution 
and kinetics of drugs in vivo. 
Due to the low specific activity, research focus was shifted towards the 
development of a different methodology for radiolabelling carbamates. The 
Mitsunobu reaction described in chapter 2 has been reported to produce 
carbonates efficiently as well as urea when non-radioactive CO2 is used.[31] The 
method developed in chapter 2 for radiolabelling ureas uses Mitsunobu reaction, 












3.2.9 Method 2 
Zopiclone (Figure 3.2) is a GABAA agonist that is used as a hypnotic agent. The 
compound has an affinity (Ki) value of 24 nM in the cerebral cortex and 31 nM in 
the cerebellum. In addition to its potential use as a PET radiotracer, it was chosen 
as a molecule to demonstrate proof-of-concept labelling using the method 
described in chapter 2. 
 
Figure 3.4 The structure of Zopiclone. 
Methylation with [11C]CH3I would be an obvious labelling strategy that comes to 
mind when considering the radiolabelling of Zopiclone. Although that would be 
ideal, the compound is metabolised into desmethylzopiclone which is also an 
active drug (Scheme 3.40).[32]  
 
 The liver metabolism of Zopiclone to desmethylzopiclon. 
Radiolabelling at the carbonyl position will enable in vivo assessment of both 
methylated and desmethylated compounds. 
Initially, reactions were performed using the previously developed method 
(chapter 2) for the radiolabeling of ureas. The obtained chromatogram did not 
show the target radiolabelled compound (expected to elute at 8.15 min). 
However, a major peak (80 %) was observed (at 7.35 min) which corresponded 
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to the 11C-labelled symmetrical urea (Figure 3.5). Three minor peaks were also 
observed; the first peak was unreacted [11C]CO2 (at 2.40 min). The labelled by-
products were also observed when the reaction was performed in the absence of 
the alcohol and the amine compound, suggesting that the peaks were Mitsunobu 
reaction by-products.  
Amines are more reactive than alcohols and the ratio of amine to alcohol in the 
first experiment was high (3: 1) which could explain the [11C]symmetrical urea 
formation. In an attempt to prevent the synthesis of [11C]symmetrical ureas, the 
concentration of the amine was reduced so that it matched the concentration of 
the alcohol. The crude product was obtained in 24 % RCC (Table 3.14, Entry 2). 
However, a reduced trapping efficiency (30 – 60 %) was also observed. BEMP 
has been reported to have a better trapping efficiency than DBU and in order to 
increase the trapping, the trapping reagent was changed to BEMP. High trapping 
efficiency of > 90 % was obtained, however, the 11C-labelled product was not 
observed (Table 3.14, Entry 3).  
To increase the trapping efficiency while using DBU, the concentration of the 
trapping reagent was increased (Table 3.14, Entries 4 and 5). Although this 
improved the trapping efficiency, the target product was not observed. The results 
indicated that an optimal concentration of DBU was essential for the reaction to 
produce the [11C]zopiclone product.  
The reaction was then performed using high concentrations of the alcohol 
compared to the amine (3:1) while keeping the concentration of the DBU constant 
(Table 3.14, Entry 6). A trapping efficiency of 70 % and a RCC of 28 % was 
observed (Figure 3.6). 
In order to increase the RCC and avoid the synthesis of a [11C]symmetrical urea, 
[11C]CO2 was bubbled into a solution containing only alcohol and DBU in CH3CN, 
and the amine subsequently added (Table 3.14, Entry 7). Increase in RCC was 






Table 3.14 Method 2 optimisation reactions. 
Entry [Base] d [ROH] [R2NH] RCC (%)e 
1a 10% 1 3 0 
2 10% 1 1 24 
3b 10% 1 3 0 
4 20% 1 1 0 
5 100% 1 1 0 
6 10% 3 1 28 
7c 10% 3 1 26 
 
a Reaction conditions: amine (18.3 µmol), alcohol (27.5 µmol), DBU (0.8 µmol), in 300 µmol 
CH3CN heated at 50 oC for 1 min, Mitsunobu reagents (36.6 µmol) in 100 µmol CH3CN 
added and stirred for 1 min. b BEMP was used as the base. c amine added after the 
trapping of [11C]CO2. d equivalence of base used. e RCC values are average of 2 (n = 2), 




Figure 3.5 The radio-HPLC chromatogram of the synthesis of [11C]symmetrical urea. The 




Figure 3.6 Radio-HPLC and UV chromatograms of the crude [11C]Zopiclone reaction co-
injected with the reference standard. The target product tr = 8:15 minutes and the symmetrical 
urea tr = 7.45 min. unreacted [11C]CO2 at 2.10 min and unknown radiolabelled by-products tr = 
10.40, 11.15, 11.45 and 12.20 min. 
 
Further attempts to increase the RCC by performing the reaction at different 
temperatures (25 oC and 40 oC) were unsuccessful and frustratingly, the product 
formation was not always reproducible. The best purification was obtained when 
a gradient HPLC method (methanol and water) were used (Figure 3.6). High 
purity of the radiotracer is essential in order to obtain reliable autoradiography. 















Carbamates and carbonates are common structural features of molecules acting 
on the GABA and glutamate receptor system. To date, there are few methods in 
which these structures can be radiolabeled with 11C. Radiolabeling this class of 
molecules offers an opportunity to deepen our understanding of GABA and 
glutamate receptor’s function by following the fate of these radiolabeled 
molecules in vivo. 
There are many non-radioactive synthetic methodologies that can be translated 
to radioactive synthesis and an example of this is the chemistry by Salvatore et 
al.[18] The reaction is ideal as it is high yielding and it can be used for the synthesis 
of both carbamates and carbonates.  
To date, there are no methods available for the radiolabelling of carbonate 
structures with 11C however, carbamates have been radiolabelled. The 
established methods to radiolabel carbamates with 11C are limited by functionality 
tolerance therefore, new radiolabeling reactions to incorporate 11C into 
carbonates and carbamate molecules are required. Novel methods would 
increase the range of radiotracers that can be synthesised.  
This work describes two methods to radiolabel carbamates with [11C]CO2 directly 
from the cyclotron. Both methods are useful additions to existing radiolabelling 
methods using [11C]CO2. The first method uses Cs2CO3 as a trapping reagent to 
produce target [11C]carbamates in high RCCs of over 80 %. The method also 
works well for the radiosynthesis of [11C]carbonates. However, products with low 
specific activity were obtained due to the introduction of non-radioactive 
carbonate into the reaction from the Cs2CO3. Although this is undesirable for 
receptor or enzyme imaging, the method can be used for other purposes 
including the study of the biodistribution and kinetics of drugs in vivo. 
The second method is a further development to our previously established 
method to radiolabel ureas. Moderate trapping and yields were observed when 





3.4.1 General  
All purchased chemicals were used without further purification. Chemicals were 
purchased in highest available purity from Sigma-Aldrich and Alfa Aesar and used 
as received (> 99 % purity). All solvents were purchased as anhydrous in highest 
available purity (> 99.8 % purity, water < 50 ppm, extra dry) from Sigma-Aldrich, 
used as received and stored under argon. Reference compounds were either 
purchased from Sigma-Aldrich or synthesised using reported procedures. 
Reactions were carried out under an atmosphere of nitrogen in heat gun dried 
glassware with magnetic stirring. Reactions were monitored using alumina plate 
thin-layer chromatography (Merck, silica gel 60, fluorescence indicator F254, or 
Merck, aluminium oxide neutral, fluorescence indicator F254). Silica gel 
chromatography was performed using 230-400 Mesh (Grade 60) silica gel. The 
mobile phase was a mixture of hexane : ethyl acetate in varying ratios and 
detected by 254 nm UV light. Infra-Red spectra were acquired on a PerkinElmer 
spectrum 100FTIR. 1H-NMR (400 MHz) and 13C-NMR (100 MHz) spectra were 
obtained using a BRUKER DRX 400 MHz spectrometer. Chemical shifts are 
reported in ppm (δ) relative to tetramethylsilane (TMS, d = 0 ppm) and calibrated 
using solvent residual peaks. Data are shown as follows: Chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling 
constant (J, Hz) and integration. Calculated mass was determined using 
PerkinElmer ChemBioDraw Ultra 13.0 program. Mass spectroscopy was 
performed at King’s College London using an Agilent 6520 Accurate-Mass Q-
TOF LC/MS connected to an Agilent 1200 HPLC system with UV detector (254 
nm) and auto-sampler. [11C]CO2 was produced by a Siemens RDS112 cyclotron 
(St Thomas’ Hospital, London, United Kingdom) via the 14N(p,α)11C nuclear 
reaction. Typical irradiation times were 1 minute with a beam current of 10 µA, 
which yielded a [11C]CO2 amount of about 300 MBq at end of bombardment. 
Radiolabelling reactions were performed in a 1.5 mL screw top vial with a “V” 
internal shape. Analytical HPLC was performed on an Agilent 2060 Infinity HPLC 
system with a variable wavelength detector (254 nm was used as default 
wavelength). An Agilent Eclipse XDB-C18 reverse-phase column (4.6 x 150 mm, 
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5 µm) was used at a flow rate of 1 mL/min and H2O/MeOH (HPLC grade solvents 
and with 0.1 % TFA) gradient elution (flow rate: 1 mL/min, 0-2 min: 5% MeOH, 2-
11 min: 5 to 95% MeOH linear gradient, 11-13 min: 90% MeOH, 13-14 min: 90% 
to 5% MeOH linear gradient, and 14-15 min:5% MeOH). The RCC was estimated 
by radio-HPLC and defined as the area under the [11C]urea peak expressed as a 
percentage of the total 11C labelled peak areas observed in the chromatogram. 
Specific radioactivity was calculated from analytical HPLC sample of 25 μL. A 
calibration curve of known mass quantity versus HPLC peak area (254 nm) was 
used to calculate the mass concentration of the 25 μL radiolabelled compound. 
The identity of the radiolabelled compound peak was confirmed by HPLC co-
injection of a nonradioactive reference compound and yielded a single peak. 
 
3.4.2 Synthesis of reference compounds 
 
Synthesis of compound 1: CO2 gas was bubbled into a solution containing 
isopropyl alcohol (61 µL, 0.8 mmol), Cs2CO3 (0.782 g, 2.4 mmol) and TBAI (0.887 
g, 2.4 mmol) in 2.5 mL DMF for 1 hour. Benzyl chloride (276 µL, 2.4 mmol) was 
then added and the reaction stirred at room temperature with CO2 gas bubbling 
through for another 3 hours. The reaction mixture was poured into water and 
extracted with ethyl acetate. The organic layer was washed with water and brine, 
and dried over sodium sulphate. The crude product was concentrated and 
purified by flash chromatography (gradient, 0% to 50%, hexane-ethyl acetate).  
19 % yield (0.029 g); IR 2924.17, 1741.12, 1259.81; 1H NMR (400 MHz, CDCl3) 
δ 7.45 (m, 5H), 5.20 (s, 2H), 5.15 (m, 1H), 1.30 (d, J = 7.1, 6H); LCMS calculated 
for C11H14O3 [M+H]+ = 195.0900; found 195.1025. The spectral data of the 





Synthesis of compound 2: CO2 gas was bubbled into a solution containing 
tetrahydroisoquinoline (101 µL, 0.8 mmol), Cs2CO3 (0.782 g, 2.4 mmol) and TBAI 
(0.887 g, 2.4 mmol) in 2.5 mL DMF for 1 hour. Benzyl chloride (276 µL, 2.4 mmol) 
was then added and the reaction stirred at room temperature with CO2 gas 
bubbling through for another 3 hours. The reaction mixture was poured into water 
and extracted with ethyl acetate. The organic layer was washed with water and 
brine, and dried over sodium sulphate. The crude product was concentrated and 
purified by flash chromatography (gradient, 0% to 50%, hexane-ethyl acetate. 34 
% yield (0.072 g); IR 2925.08, 1702.50, 1227.06; 1H NMR (400 MHz, CDCl3) δ 
7.30 (m, 9H), 5.90 (s, 1H), 5.10 (s, 2H), 4.23 (s, 2H), 3.60 (m, 2H), 3.10 (m, 2H); 
LCMS calculated for C17H17N1O2 [M+H]+ = 268.1300; found 268.1332. The 
spectral data of the synthesised product is consistent with reported values.[31] 
 
3.4.3 Radiolabelling procedure 
 
Synthesis of [11C]compound 1: [11C]CO2 from the cyclotron target was bubbled in 
a stream of helium gas at a flow rate of 1.4 mL/min post target depressurisation 
directly into a reaction vial containing TBAI (24 mg, 66 µmol), Cs2CO3 (21 mg, 66 
µmol) and isopropyl alcohol (1.65 µL, 22 µmol) in DMF (400 µL). The mixture was 
stirred at 100 oC for 5 minutes, benzyl chloride (7.5 µL, 66 µmol) was added and 
heated for a further 5 minutes before quenching the reaction with H2O and 





Synthesis of [11C]compound 2: [11C]CO2 from the cyclotron target was bubbled in 
a stream of helium gas at a flow rate of 1.4 mL/min post target depressurisation 
directly into a reaction vial containing TBAI (24 mg, 66 µmol), Cs2CO3 (21 mg, 66 
µmol) tetrahydroisoquinoline (3 mg, 22 µmol) in DMF (400 µL). The mixture was 
stirred at 100 oC for 5 minutes, benzyl chloride (7.5 µL, 66 µmol) was added and 
heated for a further 5 minutes before quenching the reaction with H2O and 
preforming the HPLC analysis. tr = 9.50 min; RCC = 90 %. 
 
 
Synthesis of [11C]Zopiclone: [11C]CO2 from the cyclotron target was bubbled in a 
stream of helium gas at a flow rate of 1.4 mL/min post target depressurisation 
directly into a reaction vial containing an an amine (1.89 µL,18.3 µmol), alcohol 
(7.1 mg, 27.5 µmol) and DBU (0.13 µL, 0.9 µmol) in CH3CN (300 µL). [11C]CO2 
from the cyclotron was bubbled in the reaction mixture and the resulting solution 
was stirred, and heated at 50 oC for 1 minute. In a separate vial, tributylphosphine 
(9 µL, 36.6 µmol) was added to a solution containing di-tert-butyl 
azodicarboxylate (8 mg, 36.6 µmol) in CH3CN (100 µL) under argon at room 
temperature. The resulting solution was transferred into the reaction mixture and 
stirred for one minute at 50 oC. The reaction was quenching it with water, the 
crude product was analysed by radio-HPLC. tr = 25.15 min; RCC = 15 %; RCY = 
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4 Chapter 4 
4.1 Introduction 
4.1.1 CNS radioligand development 
Central nervous system (CNS) radioligands are drug-like molecules that produce 
a high signal-to-noise ratio for a specific molecular target. Despite the availability 
of a number of successful PET radioligands (e.g. Table 4.1), there is still lack of 
radioligands for many CNS receptors and enzymes. The development of further 
radioligands is of great interest in furthering our understanding of in vivo 
pharmacology and brain function.[1]  
Table 4.1. Established CNS radioligands.  
 
 






Dopamine D2 receptors  
[11C]RO15-4513 [4] 
 






There are many similarities between the process of developing a CNS drug and 
a CNS radioligand, as well as many differences.[6] In drug development, drug 
candidates can fail for various reasons including low bioavailability, toxicology 
and inappropriate therapeutic windows. These are not challenges encountered 
when developing a PET radioligands as the tracer is administrated intravenously 
in subnanomolar concentrations which allows even toxic or potent compounds to 
be radiolabelled and administrated into living subjects without producing a 
pharmacological or toxicological effect.[7] When developing a novel radioligand 
for PET neuro-imaging, there are some essential design and test parameters that 
must be considered.[6, 8]  
Low Non-specific binding (NSB) 
NSB is a major contributing factor for radioligand failure. NSB can be defined as 
the binding of a radioligand to non-saturable components in tissue.[1] Despite the 
development of many methods to predict in vivo NSB, the phenomenon is poorly 
understood. The most common methods for predicting in vivo NSB are the 
partition coefficient lipophilicity (Log P) and tissue-section autoradiography.  
In PET imaging, it is generally believed that for a successful CNS radioligand, its 
Log P value should be between 1 and 3.[9] Highly lipophilic compounds are able 
to cross the blood-brain-barrier but can also bind to the surrounding tissue (non-
saturable binding) which results in high NSB. Furthermore, compounds with high 
Log P values favour binding to plasma proteins which reduces the amount of 
radioligand available to passively diffuse across the blood-brain-barrier.[1, 10] 
Conversely, compounds with low log P have limited blood-brain-barrier 
permeability due to reduced passive diffusion across the membrane.  
Kugher et al.[11] used in vitro autoradiography to study NSB. Although only four 
different 18F radiolabelled tracers were used, the study showed that the 
compound with a Log P value of 2.71 had the highest in vitro NSB (96 %) while 
the other compounds with Log P values of 2.45 and 1.81, had NSB of 80 % and 
33 %, respectively. Although only 4 sets of compounds were used, the data 




 The relationship between experimental log P and NSB.[11] 
Log P is usually measured using the shake-flask method where the compound is 
partitioned between a water and n-octanol mixture.[12] However, other methods 
such as the use of reverse-phase HPLC to determine chromatographic 
hydrophobicity index, (CHI) log D, and, an immobilised artificial membrane 
column to measure CHI_IAM have been shown to be better predictors of NSB.[12] 
log D is the value of Log P at physiological pH.  
The retention time of compounds exhibiting different retention times on the C18 
reverse phase HPLC column are used to determine CHI_logD values. CHI_logD 
is the HPLC equivalent of Log Doct/wat and can be performed at pH 7.4 to mimic 
physiological pH. Compounds with high lipophilicity have a long retention times 
while compounds with low lipophilicity have short retention times.[12] 
IAM is a reverse phase HPLC column that has a stationery phase that links a 
phosphatidylcholine (PC) head group to silica propylamine through a carboxylic 
acid group (Figure 4.2).[13] CHI_IAM is believed to be a better predictor of in vivo 
NSB as the artificial membrane mimics the biological membrane and hence, gives 











 The IAM.PC structure containing silica-propylamine and PC group.[13] 
Evidence suggests there is a relationship between Log P and NSB.[11] Most 
radioligands with low NSB have a Log P value in the range of 1 - 3. However, 
there are compounds such as WAY 100635, which have a high log P (3.28) and 
have low NSB.[14] If log P alone was used to predict NSB, WAY 100635 may have 
been excluded from radioligand development studies. This suggests that 
lipophilicity is not the only parameter that can help predict NSB.[15]  
NSB can be estimated using radioligand blocking studies in vitro. 
Autoradiography is a technique that is used to determine tissue localisation of a 
radioligand. In vitro autoradiography involves introducing the radioligand to tissue 
sections. These tissue sections are generally frozen, sectioned on a cryostat and 
thaw-mounted onto glass slides. Initially, autoradiography is performed using 
tracer levels of the radioligand. The overall binding from the first experiment gives 
the total binding (free radioligand + NSB). The autoradiography study is then 
repeated but with the addition of a high concentration (over 100 fold) of non-
radiolabelled compound that is known to bind specifically to the target site of 
interest. The second experiment would reveal the extent of the NSB (Equation 
4.1). Using estimates for the total binding and the NSB, the specific binding can 
be calculated. Generally, radioligands require > 90 % in vitro specific binding 
determined by autoradiography, to have a chance of being a successful 
radioligand in vivo.[15] 
Equation 4.1. Specific binding = Total binding – Non-specific binding. 
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NSB and lipophilicity are two of the main parameters that must be considered 
during radioligand development. Other design and test parameters must also be 
considered: 
Ease of radiolabelling  
The molecule should be amenable for rapid radiolabelling with a suitable 
radionuclide. 11C and 18F are the most commonly used radionuclides for PET 
molecular imaging.[1] There are limited number of radiolabelling methodologies 
that incorporate these radionuclides into target compounds efficiently. The 
development of methods that radiolabel compounds with these short-lived 
radionuclides are therefore important. The overall synthesis time for the 
radiolabelling reaction should be within 3 half-lives of the radionuclide and 
produce sufficient quantities of radioligand with a suitable specific activity to 
collect adequate amounts of data from the PET study.  
High Binding potential (BP) 
At the early stage of CNS radioligand development, in vitro BP measurements 
help by eliminating radioligand that are likely to fail in vivo.[16] In order to calculate 
in vitro BP, the target receptor’s density (Bmax) and the radioligands affinity to the 
target receptor (KD) are required (Equation 4.2). 
Equation 4.2. BP = Bmax / KD 
High affinity is generally required for a radioligand to successfully bind to the 
target site. Typically, most successful receptor radioligands have subnanomolar 
or low nanomolar affinity to the target site of interest. The required affinity for a 
radioligand is dependent on the density of the target receptor under study i.e. the 
lower the target density, the higher the affinity required from the radioligand. As 
a rule-of-thumb, ideal radioligands usually have an in vitro BP value of > 10 to 
produce a good signal-to-noise image in vivo.[17] Furthermore, high selectivity to 






For CNS tracers, adequate radioligand entry to the brain is essential to obtain a 
useful quantitative images. The ability for a CNS radioligand to enter the brain 
from the plasma depends on at least two factors: its ability to cross blood-brain-
barrier and its susceptibility to rejection by efflux pumps.[6, 18]  
Most PET tracers are drug-like molecules and therefore, similar factors influence 
their ability to cross the blood-brain-barrier: Log P (1 to 3), molecular weight (< 
500 Da), number of hydrogen bonds (< 10) and lack of formal charge. 
The efflux pumps in the blood-brain-barrier (e.g P-glycoprotien (P-gp)) can 
prevent compounds from accumulating in the brain.[17] To acquire sufficient 
radioligand signal in the brain, a CNS radioligand should not be a substrate for 
these proteins. Generally, most compounds that are substrates for P-gp have 
high lipophilicity, positive charge at physiological pH and multiple aromatic 
groups.[18]  
Metabolism 
If a radioligand is metabolised in vivo, it is important to exclude radiolabelled 
metabolites from contaminating the signal of the parent radioligand in the CNS. 
This is often achieved by the careful choice labelling position whereby hydrophilic 
metabolites with poor brain penetration are produced.[6]  
The above requirements are some of the most important and demanding criteria 
that must be considered for CNS radioligand development. The subsequent 
section describes the development of radioligands for the metabotropic glutamate 







4.1.2 Glutamate receptors 
There are two different types of glutamate receptors at the synaptic membrane: 
ionotropic (iGlu) receptors which are ion channel pores that activate upon 
glutamate binding; and metabotropic (mGlu) receptors which are a family of G-
protein coupled receptors.[19] mGlu receptors consist of eight subunits and are 
divided into three groups based on their signal transduction mechanism, 
pharmacology and receptor sequence homology (Table 4.2).[20] 
Table 4.2. mGluR subunits, their function, synapse site and an example of an agonist. 
Group one include mGluR1 and mGluR5, group two consists of mGluR2 and 
mGluR3 and group three includes the other 4 types. Although mGluR are 
ubiquitous in the brain, the different subtypes are highly expressed in discrete 
locations. The mGluR1 has shown to play a role in neurological and psychiatric 
disorders such as anxiety, schizophrenia and other cognition-related disorders.[21] 
Consequently, mGluR1 has become an important target for the development of 
radioligands. Developing radioligands to monitor these receptors would 
subsequently offer a valuable insight into diseases that are associated with 
mGluR1 dysfunction. 
 
4.1.3 mGluR1 radioligands 
In 2004, the first mGluR1 radioligand was developed.[22] The selective radioligand 
[3H]R214127 was used to determine the densities of mGluR1 in rat brain regions 
(Table 4.3, Entry 1). 





receptor activity  

















Table 4.3. The mGluR1 densities in different species.[9, 22] 
In 2011, Hostetler et al.[9] used 18F labelled [18F]MK-1312 to measure the 
concentration of the receptors in the cerebellum and cortex of humans and 
primates (Table 4.3, Entries 2 and 3). These Bmax values enable the minimum 
affinity requirement for a radioligand to be estimated. In order to obtain a 
minimum BP value of 10, mGluR1 radioligands require a KD value of < 5 nM in 
the cerebellum across all species.[8b] As the mGluR1 Bmax value in the cortex is 
lower than the cerebellum, a minimum radioligand KD of 2.6 nM is required across 
all species to image the region successfully.  
The Bmax and KD values differ across species (Table 4.3) and is one of the 
reasons why a successful in vitro radioligand characterised in rodents sometimes 
fails when it is translated into humans. 
11C radiolabelled mGluR1 radioligands 
In 2005, [11C]JNJ-16567083 was reported as the first PET radioligand for imaging 
mGluR1 in rats.[23] The radioligand was synthesised using palladium-mediated 
Stille coupling with [11C]CH3I (Scheme 4.1). A radiochemical yield (RCY) of 47 % 
(decay corrected and based on [11C]CH3I) and a high affinity for the mGluR1 (Ki 
= 3.49 ± 0.93 nM) was reported.  
Scheme 4.1. The synthesis of [11C]JNJ-16567083.[23] 
Entry Species 
Regional Bmax (nM) 
Cortex Cerebellum 
1 Rat 47.1 ± 6.8 430.2 ± 202.2 
2 Rhesus monkey 10 ± 1.9 53 ± 12 
3 Human 26 ± 15 82 ± 33 
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Ex vivo studies showed high radioligand uptake in the cerebellum, striatum, 
hippocampus and frontal cortex; brain regions in which mGluR1 receptors are 
localised. Subsequently, in vivo studies showed rapid brain entry with peak 
uptake 10 minutes post intravenous administration and specific mGluR1 binding 
in rats. When the radioligand was evaluated in non-human primates, high NSB in 
the brain was observed. Further studies established that the radioligand has 
lower affinity for cloned human mGluR1 compared to the cloned rat mGluR1 
(Table 4.4).[23] 




Due to the species differences in affinity and the high NSB, it was concluded that 
[11C]JNJ-16567083 was not suitable for imaging of mGluR1 in primates.[23] No 
further characterisation of the radioligand has been reported. 
After a few years of inactivity in the field of mGluR1 PET radioligand development, 
in 2010, Yanamoto et al.[24] reported a novel 11C radiolabelled tracer: [11C]YM-
202074. The precursor was labelled using the secondary synthon [11C]CH3I 
(Scheme 4.2) with RCY of 7.4 % (based on [11C]CO2 at the EOB) and a high 
affinity for the mGluR1 (Ki = 4.8 ± 0.37 nM).[24] 
 
 
Scheme 4.2. The synthesis of [11C]YM-202074. 
receptors Ki (nM) 
Cloned rat mGluR1 3.49 ± 0.93 
Cloned human mGluR1 13.3 ± 6.49 
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In vitro studies showed that the radioligand bound to mGluR1 receptors however, 
in vivo studies revealed low radioligand brain uptake and a high NSB. The results 
were unexpected as [11C]YM-202074 has high affinity for mGluR1 and an ideal 
LogD value of 2.7. In mice metabolism studies, only 5 % of the parent radioligand 
remained in plasma after 30 minutes post-injection, suggesting rapid metabolism 
of the ligand. Furthermore, [11C]YM-202074 accounted for 50 % of the 
radioactivity in the cerebellum and 10 % in the rest of the brain which suggests 
the possible entry of radioactive metabolites into the brain.[24]  
In the same year, 2010, another 11C radiolabelled mGluR1 was also established 
by Prabhakaran et al.[25] ([11C]MMTP). The compound was radiolabelled using 
[11C]CH3OTf (Scheme 4.3) with a RCY of 30 % (based on [11C]CH3OTf) and 
possessed good affinity for mGluR1 (Ki = 7.9 nM). 
 
Scheme 4.3. The synthesis of [11C]MMTP. 
Fast uptake and clearance from the brain in non-human primates were observed. 
Further, a high concentration of the radioligand was observed in the cerebellum 
compared to other regions in the brain, consistent with the known expression 
levels in non-human primates.[25] No further characterisation of the radioligand 
has been reported since. 
Another mGluR1 radioligand, [11C]ITMM, was also reported.[26] The compound 
was radiolabelled using [11C]CH3OTf (Scheme 4.4) with a RCY of 22 % (decay 
corrected and based on [11C]CO2). The affinity of the compound was determined 




Scheme 4.4. The synthesis of [11C]ITMM 
In vivo PET imaging studies in rats showed slow uptake of [11C]ITMM into the 
brain. But once taken up, high radioligand accumulation was observed in the 
cerebellum, thalamus and striatum. Further, appreciable washout from the brain 
was observed within the 90 minutes scan time. Selective binding of the 
radioligand was confirmed by comparing the binding of the ligand in wild-type 
mice and mGluR1 knock-out mice. Wild-type mice showed similar regional uptake 
to that of rats while knock-out mice showed low and uniform uptake.[26]  
In 2013, [11C]ITMM was used as the first-in-human radioligand for the molecular 
imaging of mGluR1.[27] In humans, the radioligand showed slow metabolism in 
plasma, with 61 % of the parent radioligand remaining at 60 minutes post-
injection. Slow and relatively low brain uptake was observed, with continuous 
accumulation of the radioactivity in the cerebellum. Only a small amount of 
radioligand washout was observed in other brain regions. Nevertheless, results 
indicated that [11C]ITMM bound specifically and selectively to mGluR1 receptors 
in humans.[27]  
An analogue of [11C]ITMM where the 4-methoxy group was replaced with 4-
methyl group was synthesised using palladium-mediated Stille coupling with 
[11C]CH3I (Scheme 4.5).[28] A radiochemical yield (RCY) of 19 % (decay corrected 





Scheme 4.5. The synthesis of [11C]ITMD 
Metabolite studies in rats showed minimal presence of radiometabolites in the 
brain after 60 minutes (4 – 8 %). Radiometabolites accounted for 66 % of the total 
radioactivity in the plasma at 60 minutes. This suggested that the 
radiometabolites do not enter the brain to an appreciable extent.[28] Similar results 
were observed in monkey brains, however, monkey brain uptake was relatively 
low compared to [11C]ITMM. Further kinetic studies showed that the radioligand 
displayed reversible behaviour in vivo. Blocking studies with an mGluR1 selective 
compound (JNJ-1625985) confirmed the specific binding of the new 11C 
radioligand to mGluR1.  
Finally, [11C]LY-2428703 was developed recently as a potential PET mGluR1 
radioligand (Scheme 4.6).[29] The radioligand has a good affinity for the mGluR1 
(Ki = 8.9 nM) but has a high LogD value of 4.02 ± 0.09.  
 
Scheme 4.6. The synthesis of [11C]LY-2428703 
Rapid brain uptake and washout were observed in rat brain, with the highest 
radioligand concentration measured in the cerebellum and cortex. However, low 






Table 4.5. Examples of mGluR1 PET ligands. (a) The affinity of the radioligand to rat 
cerebellum homogenate. 






JNJ-16567083 [23] [11C]CH3I 4.41 
 







ITMM [26] [11C]CH3I 12.6 
 








To date, there are no 11C radiolabelled radioligands that can be used to efficiently 
image mGluR1 in humans.[8b] Furthermore, the available 11C radiolabelled tracers 
use secondary 11C synthons and therefore, developing mGluR1 radioligands that 
can be synthesised rapidly and with a good pharmacokinetics is of significant 
interest. 
There are some 18F radioligands (such as MK-1312) that have shown good in 
vivo properties. More examples are found in references 9 and 30.[9, 30] 
 
4.1.4 Summary 
Radiolabelling molecules that interact with neurotransmitter systems offer an 
opportunity to deepen our understanding of brain diseases using molecular 
imaging techniques.  
11C radioligands are useful as they permit repeat studies in the same subject on 
the same day. There are a number of 11C labelled radioligands available for 
imaging mGluR1 receptors and although these radioligands are useful, their 
widespread use is limited by factors such as RCY, slow brain uptake, 
accumulation and slow clearance of radioactivity from brain. The development of 




To use the novel methods developed in chapter 2 and apply them to the 
development of 11C radiolabelled mGluR1 radioligands. This would demonstrate 






4.3 Development novel of mGluR1 radioligands 
4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-
3,6-dihydropyridine-1(2H)-carboxamide (FTIDC) is a highly potent and selective 
mGluR1 antagonist with an IC50 value of 5.8 nM and a Log P value of 2.1 (Figure 
4.3). In 2009, the radiolabelling of the compound was reported in a poster abstract 
using 18F.[30a] Authors stated that attempts to radiolabel the compound with 11C 
were unsuccessful. No further characterisation of the radioligand has been 
reported since. The compound contains a urea structure and therefore, it can in 
principle be radiolabelled using the novel method developed in chapter 2. 
 
 The chemical structure of FTIDC. 
In this work, a library of three structurally related compounds were synthesised in 
order to investigate the structural influences on the radiolabelling reaction.  
2-chloro-3-(5-methyl-4-(1,2,3,6-tetrahydropyridin-4-yl)-1H-1,2,3-triazol-1-
yl)pyridine (compound 1) was taken as the backbone for all the compounds as 
this core pharmacophore is found on the established mGluR1 antagonist 
FTIDC.[31] Furthermore, the synthesis of the compound is established and the 
Log P value is within the ideal range for PET tracers. The compound has a 
secondary amine present which enables it to react with various amines, in the 
presence of CO2, to form ureas. Aliphatic, aromatic and benzyl amines (Figure 






 Structure of the precursor and the designed compounds. 
 
4.3.1 Synthesis of compound 1 
The synthesis of the precursor (compound 1), reported by Ito et al.[32] , is achieved 
in five steps and includes the formation of an azide from an amine and a 
subsequent click reaction (Scheme 4.7).  
 
Scheme 4.7. The proposed route for the synthesis of compound 1. 
The synthesis of compounds 6 – 8 proceeded with yields of > 70 %. The click 
reaction is expected to produce a regioselective product. In the absence of a 
catalyst, click reactions produce a mixture of two regioisomers, however, due to 
the steric hindrance effect caused by the bulky SiBu3 group, the reaction is likely 
to produce a regioselective product. The NMR spectra of compound 7 (Figure 




 The NMR spectra of compound 7. 
The Pd-mediated reaction (the synthesis of compound 10) was challenging. 
When the reaction was performed at low concentrations (0.15 mmol of compound 
9), the target product was produced with moderate yields of 20 – 50 %. However, 
when high concentrations of compound 9 were used (0.15 mmol) the target 
product was not observed. Although only a small quantity of the precursor is 
required for each radiolabelling reaction, performing the non-radioactive 
synthesis in small quantities is time consuming. Furthermore, the reaction yields 
were in the range of 20 – 50 %. Synthesis of the target compound was 
subsequently attempted using different Pd-mediated reactions (Scheme 4.8), 





Scheme 4.8. The synthesis of compound 10. 
 
In order to produce the precursor in sufficient quantities, a different route for the 
synthesis of the precursor was proposed (Scheme 4.9). A copper-mediated 
Grignard reaction was used for the synthesis of an internal alkyne (compound 
12). The reaction between the alkyne and azide for the synthesis of compound 
10 did not proceed (Scheme 4.9). The reaction was attempted under different 
conditions and using various catalysts such as CuSO4 and CuI, however, the 
target product was not observed.  
 
Scheme 4.9. The second proposed route for the synthesis of compound 1. 
Literature reviews suggested that there were no reaction methodologies available 
for the synthesis of compound 10 from 12 due to the alkyne group being internal. 
However, numerous click reactions with terminal alkynes were available[33] and 
therefore, the possibility of eliminating the methyl group to form external alkyne 




Ito et al.[32] examined the effect of the methyl group on the compound’s affinity to 
mGluR1 receptors. Table 4.6 shows that the methyl group increases the affinity 
of the compound to mGluR1 receptors (Table 4.6, Entries 1 and 3). However, the 
selectivity of the compound to mGluR1 versus mGluR5 is higher for un-
methylated compounds. 
 






As the synthesis of the methylated compound was unsuccessful, it was decided 
that the synthesis of disubstituted [1,2,3]-triazoles, which is expected to have 
higher selectivity for mGluR1 over mGluR5, would be pursued (Figure 4.6). 
 
 Structure of the redesigned mGluR1 radioligand candidates. 
 
 
Entry R1 R2 IC50 ± SEM (nM) 
 mmGluR1 mmGluR5 
1 tBuO H 12 ± 2.2 4300 ± 1600 
2 tBuO Me 1.5 ± 0.15 170 ± 17 
3 tPrO H 180 ± 21 3900 ± 490 
4 tPrO Me 3.3 ± 0.6 40 ± 5.9 
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4.3.2 Synthesis of compound 15 
The synthesis of compound 15 included the nucleophilic substitution reaction with 
Grignard reagent to form a terminal alkyne and reacting it with an azide to form 
disubstituted [1,2,3]-triazoles (Scheme 4.10).  
 
Scheme 4.10. The proposed route for the synthesis of compound 15 
The click reaction with a terminal alkyne produced the target product efficiently. 
Copper was used to catalyse the reaction and therefore, the click reaction product 
is expected to regioselective. NMR spectra shows that the target product is 
produced efficiently (Figure 4.7).  
 




The product from the click reaction was protected with a tert-Butyloxycarbonyl 
group (boc) and therefore, the compound was added to an acidic solution to 
deprotect it and form the secondary amine (compound 15) in a high yield. 
In order to identify the HPLC retention time and characterise the radiolabelled 
compounds, the synthesised precursor was used for the synthesis of reference 
compounds. Compound 16 to 18 were successfully produced using a nucleophilic 
addition reaction. They were purified from the crude products using flash 
chromatography. The 1H NMR analyses of the compounds are shown in Figures 
4.8 to 4.10. The HPLC analysis showed that the purity of the compounds were > 
95 % (Figure 4.11).  
 





 The NMR spectra of compound 17. 
 





 The UV-HPLC chromatogram of compound 17. 
 
4.3.3 Estimation of in vivo Partition Coefficients. 
The octanol-water Partition Coefficient, Log P, is an important parameter that 
gives an insight into whether the molecule of interest has the ability to cross the 
blood-brain-barrier. The parameter also gives a prediction of a molecules in vivo 
NSB. As mentioned previously, most successful PET radioligands have a log P 
value that is in the range of 1 to 3. There are also a number of related measures 
that have been shown to be better predictors of NSB:  
CHI_logD7.4 
CHI_logD7.4 mimics the partition coefficients at physiological pH. In order to 
obtain the CHI_logD7.4 values of compounds 16 - 18, the retention time of four 
different standard compounds were initially used to obtain a calibration curve 
(Figure 4.12). The calibration curve equation was used to convert the HPLC 
retention times into CHI values. CHI values are usually between 1 and 100 and 
give an estimate of the percentage organic solvent needed for equal distribution 
of the compound between the mobile phase and stationary phase. Once CHI 
values are calculated, equation 4.3 is used to determine the CHI_logD7.4 of test 






     
 
 The retention time and CHI values of four reference standard compounds. 
Equation 4.3 CHI_LogD7.4 = (0.0525 x CHI) - 1.476 
Compound 18 had the highest CHI_logD7.4 followed by compound 16 and 17 
(Table 4.7). This is to be expected as the addition of unsaturated carbons such 
as -CH2 increase lipophilicity. Furthermore, benzylamine has a log P value of 1.09 
while aniline and cyclohexyl amine have log P values of 0.9 and 1.4 respectively. 
The addition of a reagent with a high log P value into a molecules back bone 
increases the overall log P value of the final compound. Results from the 
CHI_logD7.4 suggested that all three compounds were within the suitable range 
of successful PET radioligands. 










CHI at pH 7.4 CHI_logD7.4 
Compound 16 1.38 66.2526 2.01 
Compound 17 1.37 65.1079 1.95 
Compound 18 1.40 68.542 2.13 






A HPLC stationary phase composed of an immobilised artificial membrane can 
be used to mimic the partition of molecules between the cell membrane and its 
surrounding aqueous environment. Log KIAM is deemed superior to log P and 
CHI_logD7.4 for measuring NSB.[12] The Log KIAM values were obtained by initially 
measuring the retention time of five different standard compounds (Figure 4.13). 
A calibration curve was obtained and used to convert retention time to CHI_IAM 
values using equation 4.4. It is predicted that molecules with higher CHI_IAM 
values have higher NSB. The outcome values are used as an estimate of NSB.  
 
 
 The HPLC retention time and CHI_IAM values of reference standard 
compounds. 
Equation 4.4. Log KIAM = (0.046 x CHI IAM) + 0.42 
As expected, compound 18 had the highest Log KIAM due to having the highest 
number of unsaturated carbons (Table 4.8). The difference in Log KIAM values 
between all three compounds was very small (0.1). Nevertheless, results from 
the Log KIAM suggested that all of the compounds were within the optimal range. 
 
 











4.3.4 Radiosynthesis  
11C is produced by a cyclotron predominantly in the form of [11C]CO2. There are 
a limited number of methods available that use [11C]CO2 directly for radiolabelling 
molecules of interest.[34] In chapter 2, a direct and rapid radiolabelling 
methodology that incorporated [11C]CO2 into amines for the synthesis of ureas 
was developed. The method was subsequently utilised for the radiolabelling of 
mGluR1 radioligand candidates. The precursor, compound 15, was reacted with 
aliphatic, aromatic and benzylic amines in the presence of [11C]CO2 (Scheme 
4.11).  
 
Scheme 4.11. The radiosynthesis of the mGluR1 tracer candidates. 
[11C]CO2 was bubbled into a solution containing an amine, compound 15 and 
DBU in CH3CN. At the EOB, the solution was stirred at 50 oC for one minute. 
Mitsunobu reagents in CH3CN were added and the solution was heated for a 







CHI_IAM Log KIAM 
Compound 16 2.25 31.54 1.87 
Compound 17 2.27 32.2332 1.90 
Compound 18 2.28 32.9264 1.93 
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Table 4.9. The radiochemistry reaction steps. 
Time (minutes) Activity 
0:00 EOB 
1:00 Addition of Mitsunobu reagents 
2:00 Start of purification 
37:00 End of HPLC purification. 
The main by-product from the 11C radiolabelling reaction was unreacted [11C]CO2 
(70 %) which eluted at the solvent front. Other by-products, such as the 
symmetrical urea, were also observed. Semi-preparative HPLC was used to 
purify each radioligand. An example of a UV and a radio-chromatogram of the 
crude product is shown in figure 4.14. A radio-chromatogram of the purified 
compound is shown in figures 4.15. Although the mass of the product was low 
(1- 4 µmol), there were small amounts of unknown impurities in the purified 












 The crude (a) radio-HPLC chromatograms (b) UV-HPLC chromatograms radio-
















 The radio-HPLC chromatograms of the purified compound 17. 
 
 The UV-HPLC chromatogram of purified compound 17. 
Compounds 16, 17 and 18 were synthesised with an overall RCYs of 10, 8, and 
12 %, respectively (based on starting [11C]CO2 and uncorrected for decay). A 
radiochemical purity of > 95 % with an overall synthesis time of 21 minutes from 
the EOB (including purification) and a specific activity of 2 ± 1.8 GBq/µmol were 
obtained. 
The specific activity of the compounds were relatively low (2 ± 1.8 GBq/µmol) 
compared to the desired specific activity for imaging applications (> 50 











beam currents (5 – 10 µA) were used. In clinical productions at our facility, a 
cyclotron bombardment times of 50 minutes and beam currents of 30 µA are used 
to produce higher amounts of radioactivity (typically 60 GBq). The mass of the 
radiolabelled compounds were in the range of 0.2 – 0.9 µmol. It is therefore 
estimated that this would increase the specific activity of the purified product to 
25 - 50 GBq/µmol at EOS. 
 
4.4 Conclusion 
Metabotropic glutamate 1 receptors are linked to many diseases including 
Alzheimer’s disease and autism. Developing radioligands that bind to these 
receptors would offer a valuable opportunity to deepen our understanding of 
these diseases by following the fate of these radiolabelled molecules in vivo. In 
this project, a library of candidate compounds were designed and successfully 
synthesised using traditional organic chemistry. HPLC methods used to predict 
the NSB of the compounds indicated that candidates CHI_logD7.4 and log KIAM 
are within the ideal range for minimising in vivo NSB whilst maintaining sufficient 
brain penetration. 
The candidates were radiolabelled with [11C]CO2 using the strategy described in 
chapter 2. The method enables rapid incorporation of [11C]CO2 into reactive and 
stable amines for the synthesis of 11C radiolabelled ureas. An isolated RCY of 
16.4 % ± 8 (corrected for decay) was obtained. The overall synthesis time 
including purification was 21 minutes from the EOB and a specific activity of 2 ± 
1.8 GBq/µmol was obtained for the radiosynthesis. For imaging applications, it is 
estimated that specific activity of 25 - 50 GBq/µmol can be obtained for a standard 
11C cyclotron bombardment at our facility. In vitro autoradiography studies of the 






All purchased chemicals were used without further purification. Chemicals were 
purchased in highest available purity from Sigma-Aldrich and Alfa Aesar and used 
as received (> 99 % purity). All solvents were purchased as anhydrous in highest 
available purity (> 99.8 % purity, water < 50 ppm, extra dry) from Sigma-Aldrich, 
used as received and stored under argon. Reference compounds were either 
purchased from Sigma-Aldrich or synthesised using reported procedures. 
Reactions were carried out under an atmosphere of nitrogen in heat gun dried 
glassware with magnetic stirring. Reactions were monitored using alumina plate 
thin-layer chromatography (Merck, silica gel 60, fluorescence indicator F254, or 
Merck, aluminium oxide neutral, fluorescence indicator F254). Silica gel 
chromatography was performed using 230-400 Mesh (Grade 60) silica gel. The 
mobile phase was a mixture of hexane : ethyl acetate in varying ratios and 
detected by 254 nm UV light. Infra-Red spectra were acquired on a PerkinElmer 
spectrum 100FTIR. 1H-NMR (400 MHz) and 13C-NMR (100 MHz) spectra were 
obtained using a BRUKER DRX 400 MHz spectrometer. Chemical shifts are 
reported in ppm (δ) relative to tetramethylsilane (TMS, d = 0 ppm) and calibrated 
using solvent residual peaks. Data are shown as follows: Chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling 
constant (J, Hz) and integration. Calculated mass was determined using 
PerkinElmer ChemBioDraw Ultra 13.0 program. Mass spectroscopy was 
performed at King’s College London using an Agilent 6520 Accurate-Mass Q-
TOF LC/MS connected to an Agilent 1200 HPLC system with UV detector (254 
nm) and auto-sampler. [11C]CO2 was produced by a Siemens RDS112 cyclotron 
(St Thomas’ Hospital, London, United Kingdom) via the 14N(p,α)11C nuclear 
reaction. Typical irradiation times were 1 minute with a beam current of 10 µA, 
which yielded a [11C]CO2 amount of about 300 MBq at end of bombardment. 
Radiolabelling reactions were performed in a 1.5 mL screw top vial with a “V” 
internal shape. Analytical HPLC was performed on an Agilent 2060 Infinity HPLC 
system with a variable wavelength detector (254 nm was used as default 
wavelength). An Agilent Eclipse XDB-C18 reverse-phase column (4.6 x 150 mm, 
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5 µm) was used at a flow rate of 1 mL/min and H2O/MeOH (HPLC grade solvents 
with 0.1 % TFA) gradient elution (flow rate: 1 mL/min, 0-2 min: 5 % MeOH, 2-11 
min: 5 to 95 % MeOH linear gradient, 11-13 min: 90 % MeOH, 13-14 min: 90 % 
to 5 % MeOH linear gradient, and 14-15 min: 5 % MeOH). An Agilent ZORBAX 
GF-250 column (9.4 x 250 mm, 4 µm) was used for the purification of the crude 
product, a flow rate of 5 mL/min and H2O/MeOH (0.1 % TFA) gradient elution 
(flow rate: 5 mL/min, 0-5 min: 5 % MeOH, 5-25 min: 5 to 95 % MeOH linear 
gradient, 25-27 min: 95 % MeOH, 27-32 min: 95 % to 5 % MeOH linear gradient, 
and 32-35 min: 5 % MeOH). The RCC was estimated by radio-HPLC and defined 
as the area under the [11C]urea peak expressed as a percentage of the total 11C 
labelled peak areas observed in the chromatogram. Specific radioactivity was 
calculated from analytical HPLC sample of 25 μL. A calibration curve of known 
mass quantity versus HPLC peak area (254nm) was used to calculate the mass 
concentration of the 25 μL radiolabelled compound. The identity of the 
radiolabelled compound peak was confirmed by HPLC co-injection of a 
nonradioactive reference compound and yielded a single peak. 
 
4.5.2 Synthesis of reference compounds 
 
CAUTION: Organic azides are potentially explosive substances and the 
proposed synthesis needs to be conducted in a well-ventilated exhaust hood. 
Azides also react with metals and disposal must be highly diluted. 
Synthesis of compound 6: H2SO4 (1.2 mL) in H2O (7 mL) was heated at 55 oC for 
5 minutes, 2-Chloro-3-pyridinamine (0.500 g, 3.89 mmol) was added and heated 
for further 5 minutes. The solution was cooled to 0 oC and NaNO2 (0.55 g, 4.67 
mmol) in H2O (5 mL) was added over 15 minutes. The solution was stirred for 20 
minutes at 0 oC and urea (0.08 g, 7.70 mmol) was added and stirred for further 
20 minutes. NaN3 (0.55 g, 4.67 mmol) in H2O (5 mL) was added over 1 hour and 
mixture was stirred at 0 oC for further 20 minutes. The solution was then allowed 
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to cool to room temperature and stirred for 2 hours. Reaction was quenched with 
NaHCO3, extracted with diethyl ether, dried over MgSO4, carefully concentrated 
and purified with silica gel (Hexane/EtOAc). Yellow liquid; 82% yield (0.495 g); IR 
2105.81, 1562.19, 1411.77, 1299.37 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.03 (m, 
1H), 7.50 (m, 1H), 7.28 (m, 1H). HPLC-MS m/z: calculated for [M + H+] = 129.56; 
found 129.4520.  
 
 
CAUTION: Organic azides are potentially explosive substances and the 
proposed synthesis needs to be conducted in a well-ventilated exhaust hood. 
Azides also react with metals and disposal must be highly diluted. 
Synthesis of compound 7: tributyl(prop-1-yn-1-yl)stannane (0.33 g, 1.63 mmol) 
was added to compound 6 (0.2 g, 1.29 mmol) in toluene (2 mL) and stirred at 120 
oC overnight. Reaction was cooled to room temperature and purified with silica 
gel (Hexane/EtOAc). Yellow liquid; 73% yield (0.593 g); IR 2924.47, 2924.47, 
1473.72, 1419.83, 1066.34, cm-1; 1H NMR (400 MHz, CDCl3) δ 8.40 (m, 1H), 8.00 
(m, 1H), 7.40 (m, 1H), 2.30 (s, 3H), 1.55 (t, J = 6.4, 6H), 1.20 (m, 12H), 0.90 (t, J 
= 6.6, 9H); HPLC-MS m/z: calculated for [M + H+] = 484.14; found 484.1620. The 
spectral data of the synthesised is consistent with reported values.[32] 
 
Synthesis of compound 8: Compound 7 (0.30 g, 0.622 mmol) in THF (3.5 mL) 
was added to I2 (0.20 g, 0.778 mmol) in THF (3 mL) dropwise at 0 oC. The reaction 
was stirred for 5 minutes then allowed to cool to room temperature and stirred for 
further 3 hours. Mixture was diluted with EtOAc and quenched with Na2S2O3. 
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Organic layer extracted, dried over MgSO4, concentrated and purified with silica 
gel (Hexane/EtOAc). Yellow liquid; 92 % yield (0.183 g); IR 1507.93, 1472.97, 
1415.63 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.55 (m, 1H), 7.80 (m, 1H), 7.50 (m, 
1H), 2.30 (s, 3H); HPLC-MS m/z: calculated for [M + H+] = 320.93; found 
320.9106. The spectral data of the synthesised is consistent with reported 
values.[32] 
 
Synthesis of compound 10: Compound 8 (0.040 g, 0.125 mmol), compound 9 
(0.046 g, 0.150 mmol) and K2CO3 (0.033 g, 0.240 mmol) were added to 
PdCl2(dppf)2 (0.010, 0.013 mmol) in DMF (1.5 mL). The reaction mixture was 
stirred at 90 °C overnight. Mixture was diluted with water (15 mL) and extracted 
with DCM (x 2) and EtOAc (x 2). The combined organic fractions was dried 
(MgSO4) and concentrated. 1H NMR and LCMS of the crude product did not show 
the target product. 
 
Synthesis of compound 10: Compound 8 (0.040 g, 0.125 mmol), compound 9 
(0.046 g, 0.150 mmol) and Na2CO3 (0.033 g, 0.375 mmol) were added to Pd 
(PPh3)4 (0.022 g, 0.019 mmol) in dioxane (1.5 mL) and H2O (0.1 mL). The 
reaction mixture was heated at 100 °C using microwave for 2 hours. Mixture was 
diluted with water (4 mL) and extracted with DCM (x 2) and EtOAc (x 2). The 
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organic layer was dried over MgSO4, concentrated and purified using combiflash 
(Hexane/EtOAc). Yellow solid; 32 % yield (0.047 g); HPLC-MS m/z: calculated 
for [M + H+] = 376.15; found 376.1609. 
 
 
Synthesis of compound 1: TFA (192 µL) was added to a solution containing 
compound 10 (0.028 g, 0.076 mmol) in DCM (0.8 mL) at 0 oC. The reaction was 
warmed to room temperature and stirred overnight. 1N NaOH (8 mL) was added 
to the mixture and extracted with DCM (3 x 10 mL). The organic layer was washed 
with brine, dried with Na2SO4, and concentrated. Yellow solid; 100 % yield (0.021 
g); HPLC-MS m/z: calculated for [M + H+]= 276.73; found 276.8230.  
 
Synthesis of compound 12: compound 11 (0.083 g, 0.25 mmol), Co(acac)3 (0.003 
g, 0.008 mmol) in THF was added to prop-1-yn-1-ylmagnesium bromide (0.064 
g, 0.45 mmol) and stirred at 40 oC overnight. Reaction was quenched with 0.1M 
HCl (10 mL), extracted with diethyl ether (x 3). The organic layer was washed 
with brine, dried with MgSO4, and concentrated. No purification was required. 
Dark yellow liquid; 66 % yield (0.036 g); 1H NMR (400 MHz, CDCl3) δ 5.85 (t, J = 
9.5, 1H), 3.90 (m, 2H), 3.41 (m, 2H), 2.13 (m, 2H), 1.98 (m, 2H), 1.80 (s, 3H), 





Synthesis of compound 10: compound 12 (0.1 g, 0.45 mmol) was added to 
compound 6 (0.09 g, 0.585 mmol) in toluene (5 mL) and stirred at 120 oC 




Synthesis of compound 13: Compound 11 (0.250 g, 0.755 mmol), Co(acac)3 
(0.008 g, 0.022 mmol) in THF (2 mL) was added to ethynylmagnesium bromide 
(0.195 g, 1.51 mmol) and stirred at 40 oC overnight. Reaction was quenched with 
0.1M HCl (10 mL), extracted with diethyl ether (3 x 10 mL). The organic layer was 
washed with brine, dried with MgSO4, and concentrated. Compound was purified 
by flash chromatography (Hexane/EtOAc). Colourless solid; 67 % yield (0.104 g);  
IR 3289, 3240, 2974, 2929, 2838, 1658, 1413 cm-1; 1H NMR (400 MHz, CDCl3) δ 
6.10 (t, J = 9.7, 1H), 3.97 (m, 2H), 3.50 (m, 2H), 2.90 (s, 1H), 2.26 (m, 2H), 1.47 






CAUTION: Organic azides are potentially explosive substances and the 
proposed synthesis needs to be conducted in a well-ventilated exhaust hood. 
Azides also react with metals and disposal must be highly diluted. 
Synthesis of compound 14: compound 6 (0.212 g, 1.37 mmol) and compound 13 
(0.237 g, 1.14 mmol) were added to a round bottom flask containing H2O (2.3 
mL) and t-BuOH (2.3 mL). Reaction mixture was stirred at room temperature for 
5 minutes before adding CuSO4 (17.5 µL, 1 M) and sodium ascorbate (175 µL, 1 
M). The mixture was stirred at room temperature overnight. H2O was added to 
the mixture and extracted with DCM. The organic layer was washed with brine, 
saturated NaHCO3, dried with MgSO4 and concentrated. Compound was purified 
by flash chromatography (Hexane/EtOAc). Yellow solid; 67 % yield (0.280 g); 1H 
NMR (400 MHz, CDCl3): δ 8.56 (m, 1H), 8.04 (m, 1H), 8.00 (s, 1H), 7.50 (m, 1H), 
6.57 (t, J = 4.9, 1H), 4.14 (m, 2H), 3.67 (m, 2H), 2.59 (m, 2H), 1.49 (s, 9H). 
 
Synthesis of compound 15: HCl (8.5 mL, 4 M) was added to a solution containing 
compound 14 (0.615 g, 1.70 mmol) in dioxane (5 mL) and H2O (5 mL). The 
reaction was stirred at room temperature overnight and concentrated. Yellow 
solid; 61 % yield (0.374 g);. 1H NMR (400 MHz, CD3OD) δ 8.56 (m, 1H), 8.39 (s, 
1H), 8.09 (m, 1H), 7.61 (m, 1H), 6.57 (s, 1H),4.48 (m, 2H), 3.04 (m, 2H), 2.51 (s, 
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2H). 13C NMR (100 MHz, CD3OD): 152.1, 149.9, 147.3, 138.4, 133.6, 127.1, 
125.3, 125.0, 123.5, 45.2, 43.2, 27.1. HPLC (linear gradient from 20 % to 100 % 
ACN over 15 min): tr = 8.17 min, purity = 95 %. HPLC-MS m/z: calculated for [M 
+ H+] = 362.08; found 362.1003. 
 
Synthesis of compound 16: Compound 15 (40 mg, 0.152 mmol) in THF (10 mL) 
was added to (isocyanatomethyl)benzene (128 µL, 1.04 mmol) and stirred at 
room temperature for 1 hour. The mixture was concentrated and purified by flash 
chromatography (EtOAc to 10 % MeOH/EtOAc). White solid; Yield = 81 % (44 
mg);  IR 3377, 3265, 3062, 2921, 1637, 1593, 1535, 1235 cm-1; 1H NMR (400 
MHz, CDCl3) δ 8.49 (m, 1H), 7.97 (m, 1H), 7.96 (s, 1H), 7.43 (m, 1H), 7.26 (m, 
5H), 6.51 (m, 1H), 4.8 (s, 1H), 4.41 (m, 2H), 4.04 (m, 2H), 3.67 (m, 2H), 2.56 (m, 
2H). 13C NMR (100 MHz, CDCl3): 157.4, 150.2, 147.9, 144.8, 139.3, 135.8, 
132.0, 128.6, 127.7, 127.3, 126.6, 123.4, 121.3, 120.5, 44.9, 43.5, 26.4. HPLC 
(linear gradient from 20 % to 100 % ACN over 15 min): tr = 9.11 min, purity = 
98.5%. HPLC-MS m/z: calculated for [M + H+] 395.13, found 395.1368 (M + H+, 






Synthesis of compound 17: Compound 15 (40 mg, 0.152 mmol) in THF (10 mL) 
was added to isocyanatobenzene (128 µL, 1.04 mmol) and stirred at room 
temperature for 1 hour. The mixture was concentrated and purified by flash 
chromatography (EtOAc to 10 % MeOH/EtOAc). Pale yellow solid; Yield = 82 % 
(47 mg); IR 3325, 3131, 2922, 1624, 1527, 1476, 1387 cm-1; 1H NMR (400 MHz, 
CDCl3) 8.49 (m, 1H), 7.97 (m, 1H), 7.96(s, 1H), 7.43 (m, 1H), 7.31 (m, 2H), 7.21 
(m, 2H), 6.98 (m, 1H), 6.54 (s, 1H), 6.45 (s, 1H), 4.15 (m, 2H), 3.71 (m, 2H), 2.61 
(m, 2H). 13C NMR (100 MHz, CDCl3): 154.4, 150.2, 147.8, 144.8, 138.8, 135.8, 
128.9, 126.2, 123.4, 123.2, 121.1, 120.6, 120.1, 43.9, 40.0, 26.4. HPLC (linear 
gradient from 20% to 100% ACN over 15 min): tr = 9.15 min, purity = 98.1%. 
HPLC-MS m/z: calculated for [M + H+] 381.12, found 381.1209   (M+H+, 35Cl), 
383.1200 (M+H+, 37Cl), 403.1034 (M+Na+, 35Cl), 405.1025 (M+Na+, 37Cl). 
 
 
Synthesis of compound 18: Compound 15 (40 mg, 0.152 mmol) in THF (10 mL) 
was added to isocyanatocyclohexane (128 µL, 1.04 mmol) and stirred at room 
temperature for 1 hour. The mixture was concentrated and purified by flash 
chromatography (EtOAc to 10 % MeOH/EtOAc). white solid; Yield = 84 % (49 
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mg); IR 3342, 3153, 2926, 2852, 1615, 1528, 1228 cm-1; 1H NMR (400 MHz, 
CDCl3) 8.54 (m, 1H), 8.01(m, 2H), 7.48 (m, 1H), 6.56 (m, 1H), 4.42 (s, 1H), 4.02 
(m, 2H), 3.64 (m, 3H), 2.57 (m, 2H), 1.93 (m, 2H), 1.66 (m, 2H), 1.16 - 1.57 (m, 
6H). 13C NMR (100 MHz, CDCl3): 156.8, 150.1, 147.9, 144.8, 135.8, 131.9, 126.0, 
123.4, 121.4, 120.5, 49.4, 43.4, 39.4, 33.9, 26.4, 25.5, 25.0. HPLC (linear 
gradient from 20 % to 100 % ACN over 15 min): tr = 9.58 min, purity = 98.5%. 
HPLC-MS m/z: calculated for [M + H+] 387.13, found 387.1699 (M+H+, 35Cl), 




HPLC was performed on an Agilent 1200 system with a UV wavelength detector 
(254 nm) and radio-detector. Luna C18 column (50 x 30 mm, 25µm) was used 
with the following mobile phase condition: Solvent A: 50 mM ammonium acetate 
buffer (pH 7.4); solvent B: acetonitrile. The HPLC was performed at a flow rate of 
1 mL/min. four different compounds were used to create a calibration curve 
(acetophenone, propiophenone, valerophenone and acetanilide). All samples 
were prepared on 1 mL/mg solution using 50:50 solvent A and B, and 20 um was 
used for HPLC. Retention time of all reagents were converted to Log D7.4 using 
equation 4.3 where CHI is the obtained from the calibration curve. 
Equation 4.3: CHI_LogD7.4 = (0.525 x CHI) - 1.476 
logKIAM 
HPLC was performed on an Agilent 1200 system with a UV wavelength detector 
(254 nm) and radio-detector. Immobilised artificial membrane PC2 HPLC column 
(150 x 4.6 mm, 12 µm) was used with the following mobile phase conditions: 
Solvent A: 50 mM ammonium acetate buffer (pH 7.4); solvent B: acetonitrile. The 
HPLC was performed at a flow rate of 2 mL/min. Five different compounds were 
used to create a calibration curve (acetophenone, propiophenone, butrophenone, 
valerophenone and acetanilide). All samples were prepared on 1 mL/mg solution 
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using 50:50 solvent A and B, and 20 um was used for HPLC. Retention time of 
all reagents were converted to CHI_IAM using equation X where CHI_IAM is the 
obtained from the calibration curve. 
Equation 4.4: Log KIAM = (0.046 x CHI IAM) + 0.42 
 
4.5.4 Radiolabelling procedure 
 
Synthesis of [11C]compound 16: Compound 15 (10 mg, 27.5 µmol) was added to 
a vail containing benzylamine (2 µL, 18.3 µmol) and DBU (0.13 µL, 0.9 µmol) in 
CH3CN (300 µL). [11C]CO2 from the cyclotron was bubbled into the reaction 
mixture and the resulting solution was stirred, and heated at 50 oC for 1 minute. 
In a separate vial, tributylphosphine (9 µL, 36.6 µmol) was added to a solution 
containing di-tert-butyl azodicarboxylate (8 mg, 36.6 µmol) in CH3CN (100 µL) 
under argon. The resulting solution was transferred into the reaction mixture and 
stirred for one minute at 50 oC and purified by HPLC. tr = 25.15 min; RCC = 16 







Synthesis of [11C]compound 17: Compound 15 (10 mg, 27.5 µmol) was added to 
a vail containing cyclohexylamine (1.67 µL, 27.5 µmol) and DBU (0.13 µL, 0.9 
µmol) in CH3CN (300 µL). [11C]CO2 from the cyclotron was bubbled into the 
reaction mixture and the resulting solution was stirred and heated at 50 oC for 1 
minute. In a separate vial, tributylphosphine (9 µL, 36.6 µmol) was added to a 
solution containing di-tert-butyl azodicarboxylate (8 mg, 36.6 µmol) in CH3CN 
(100 µL) under argon. The resulting solution was transferred into the reaction 
mixture and stirred for one minute at 50 oC and purified by HPLC. tr = 25.43 min; 
RCC = 13 %; RCY = 8 % (uncorrected for decay); RCP = > 95 %; specific activity 
= 2 ± 1.8 GBq/µmol.  
 
Synthesis of [11C]compound 18: Compound 15 (10 mg, 27.5 µmol) was added to 
a vail containing cyclohexylamine (2.1 µL, 27.5 µmol) and DBU (0.13 µL, 0.9 
µmol) in CH3CN (300 µL). [11C]CO2 from the cyclotron was bubbled into the 
reaction mixture and the resulting solution was stirred and heated at 50 oC for 1 
minute. In a separate vial, tributylphosphine (9 µL, 36.6 µmol) was added to a 
solution containing di-tert-butyl azodicarboxylate (8 mg, 36.6 µmol) in CH3CN 
(100 µL) under argon. The resulting solution was transferred into the reaction 
mixture and stirred for one minute at 50 oC. The reaction was quenched with H2O 
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(0.5 mL) and purified by HPLC. tr = 27.05 min; RCC = 12 %; RCY = 6.5 % 
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PET is a non-invasive molecular imaging technique that provides quantitative 
data on the biodistribution and kinetics of radiolabelled molecules in vivo. The 
use of the technique has increased over the last decades due to the high 
sensitivity of PET which makes it ideal for in vivo medical diagnosis, medical 
research and drug studies. Carbon-11 (11C) is one of the most commonly used 
radionuclides for PET molecular imaging. The presence of carbon in all naturally 
occurring organic molecules makes 11C an attractive positron emitter: substituting 
the naturally abundant carbon-12 in biological molecules with radioactive 11C has 
no effect on its biological activity. 11C is produced by a cyclotron, most commonly 
in the form of [11C]CO2 and it is usually converted into more reactive species such 
as [11C]methyl iodide and [11C]carbon monoxide for radiolabelling. Although these 
reactive species are useful for radiolabelling, 11C has a half-life of 20.4 minutes 
and therefore, avoiding the conversion of [11C]CO2 to other forms provides a 
strategy to shorten synthesis times. 
There are a limited number of methods that incorporate [11C]CO2 directly into 
target molecules of interest.[1] 
In this thesis, a novel radiolabelling reaction that efficiently incorporates [11C]CO2 
directly into [11C]carbamates and [11C]carbonates has been developed. The rapid 
methodology produced target radiolabelled products in high radiochemical yields 
(> 80 %) and in a short reaction times (10 minutes). The strategy enables the 
radiolabelling of carbonates which were previously inaccessible for 11C 
radiolabelling. This reaction is therefore a useful addition to the arsenal of 
methodologies available for 11C radiolabelling. However, due to the presence of 
carbonate (from Cs2CO3), the reaction resulted in specific activities in the range 
of 1 - 10 GBq/µmol (mass range: 10 - 50 µmol). Although this is undesirable for 
imaging receptors or enzymes expressed at very low concentrations, the method 
can be used for other purposes including the study of the biodistribution and 
kinetics of drugs in vivo. 
Ureas are functional groups found in numerous drugs (e.g. phenacedine and 
ZJ43). Although there are methods available to radiolabel ureas with [11C]CO2, 
these methods are limited to radiolabelling aliphatic and benzylic compounds and 
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therefore, developing robust methods to radiolabel aromatic amines is of 
considerable interest. A rapid radiolabelling methodology that incorporates 
[11C]CO2 directly into amines for the synthesis of 11C labelled ureas was 
developed. The new radiolabelling reaction produced high radiochemical yields 
similar to that reported in the literature (up to 95 %) when aliphatic and benzylic 
amines were synthesised. However, in contrast to existing reactions, the new 
methodology produced much higher radiochemical yields for unreactive amines 
such as aniline (up to 91 %) compared to the methods described in the literature 
(6 %).[1b] The synthetic method can be carried out in less than 5 minutes from the 
end of bombardment and is robust. 
Reaction mechanism studies suggest that 1,8-diazabicycloundec-7-ene (DBU) 
and an amine are required in order to trap the [11C]CO2 within the solution. The 
trapping method is reversible: 11C is released from the mixture when the reaction 
mixture is heated to 60 oC. When Mitsunobu reagents are added to the reaction 
mixture, a phosphine oxonium ion intermediate is formed which undergoes 
nucleophilic attack to produce the target [11C]urea. 
The developed method was used in the proof-of-concept for the radiolabelling of 
three urea-containing target molecules. These molecules had different structural 
features including aliphatic, aromatic and benzylic amines and were designed as 
potential mGluR1 radiotracers. Design parameters for the molecules predicted 
good biological activity and low non-specific binding (radiotracers have a 
CHI_logD7.4 and Log KAIM value that is in the range of 1 – 3). All of the molecules 
were successfully radiolabelled with an isolated radiochemical yield of 8.2 % ± 4 
based on the starting [11C]CO2 (uncorrected for decay), > 95 % radiochemical 
purity, total synthesis time of 21 minutes from the end of bombardment (including 
purification) and specific activity of 2 ± 1.8  GBq/µmol. The experiments were 
performed with short cyclotron bombardment times, so the low specific activity 
can be improved by increasing the cyclotron bombardment time from 1 minute to 
50 minutes. The amount of target compounds produced was in the range of 0.2 
– 0.9 µmol. It is estimated for an extended 11C target bombardment that specific 
activities in the range of 25 – 50 GBq/µmol are easily achievable. The 
radiolabelled candidate’s binding to mGluR1 receptors are currently being 
evaluated using autoradiography and homogenate binding assays. 
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It has been shown that in some cases, similar reaction conditions can be used 
for the synthesis of ureas and carbamates.[1b, 2] The method for the synthesis of 
[11C]ureas was used for radiolabelling Zopiclone, a carbonate-containing 
compound that binds to GABA receptors. Reaction optimisation was required in 
order to obtain a RCY of 28 % (determined by HPLC). Purification and in vitro 





















5.2 Future work  
5.2.1. mGluR1 radiotracer development 
Purification  
HPLC was chosen as the purification method for the radiolabelling reactions. 
Isolated compounds with a radiochemical purity of > 95 % were obtained for the 
potential mGluR1 radiotracers which is usually suitable for in vivo and in vitro 
imaging applications. However, small amounts of non-radioactive impurities were 
observed on the UV-HPLC of the isolated compound. Although these unknown 
impurities are only present in small quantities and may not affect the biological 
studies, highly pure radiotracers are important to obtain reliable results. Water 
and methanol were used as the HPLC solvents in the described experiments. 
Choosing different HPLC eluents, buffers and columns might improve the 
efficiency of the existing purification method. Solid-phase extraction (SPE) might 
also be a method to increase the chemical purity further. 
 
Specific activity 
A specific activity of 2 ± 1.8 GBq/µmol was obtained when the potential mGluR1 
radiotracers were radiolabelled in chapter 4. The specific activity of the 
compounds are relatively low compared to the desired specific activity (> 50 
GBq/µmol). There are several ways that the specific activity could be increased: 
1. As the mass of the radiolabelled compounds was suitable for in vivo 
imaging (10 – 40 µmol), increasing the cyclotron bombardment time from 
1 minute to 50 minutes will increase the specific activity. It is estimated 
that this would result in specific activities of 30 – 50 GBq/µmol, a similar 
specific activity value routinely obtained for other 11C compounds in our 
laboratory. 
2. Automating the labelling procedure. One of the main disadvantages of 
using [11C]CO2 directly is the potential for isotopic dilution from 
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atmospheric CO2. Developing an automated system may reduce isotopic 
dilution from atmospheric CO2 and hence, increase the specific activity. 
The development of an automated system for direct [11C]CO2 labelling is 
currently in progress (Figure 5.1). 
[11C]CO2 is delivered into the automated system in a stream of helium 
gas. The gas passes through valves 1 (Figure 1) and bubble into the 
reaction mixture. Any gases that are not trapped within the reaction 
mixture will escape through valve 2 into a waste bag. The reaction 
mixture is heated at 50 oC for a minute and the Mitsunobu reagents are 
added to the reaction mixture via valve 2. The reaction mixture is heated 
for a further minute before being transferred to a HPLC column via valves 
3. The HPLC fraction containing the pure compound will be sent through 
valves 4, and collected. Nitrogen gas will be used to transfer reagents to 
minimise atmospheric CO2 contamination. 
 
 







In vitro autoradiography is an experimental technique that is used to estimate 
NSB. Autoradiography experiments will be carried out using the tracers 
radiolabelled in chapter 4. The experiments will determine whether the 
compounds specifically bind to mGluR1 receptors.  
Male Wistar rat tissue sections will be used during the autoradiography 
experimental procedure. Tissue sections will be prepared by isolating the brain 
from a rat and rapidly freezing it in isopentane (- 40 oC) and stored at - 80 oC until 
required. The rat brain will be sectioned using cryostat in the sagittal plane (20 
µm thickness) and will be thaw-mounted on superfrost glass slides. The slides 
will be stored in – 80 oC until required for use. 
Initially, autoradiography studies will be performed using different radiotracer 
concentrations and different incubation times. Once an optimal time and 
concentration is determined, competition binding studies to calculate NSB will be 
carried out. In competition binding experiments, the specific binding of a 
radiotracer will be determined in the presence of a competing unlabelled 
compound. An unlabelled compound with high affinity for mGluR1 should be 
chosen for use in competition binding studies.  
 
Affinity 
Appropriate affinity is one of the essential design and test parameters that must 
be considered during radiotracer development. The most promising in vivo 
mGluR1 radiotracers (e.g. [11C]ITMM and [11C]MMTP) have Ki values < 15 nM. 
mGluR1 are predominantly found in the cerebellum, which can be homogenised 
mechanically in buffer and used to determine the Ki value of the test compounds. 
Binding studies will be performed using non-radioactive candidate compounds 
and a known selective mGluR1 tritium labelled compound ([3H]YM-202074).  
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5.2.2. [11C]CO2 method development  
As previously mentioned in this thesis, there are many traditional organic 
syntheses that incorporate CO2 into target structures. These methods can be 
used as a starting point to develop [11C]CO2 radiolabelling methodologies.  
Carboxylic acids are found in a plethora of biologically active molecules and 
although there is an existing method to radiolabel carboxylic acids using 
[11C]CO2, it requires the use of boronic esters (Scheme 5.1).[1a]  
 
Scheme 5.1: The developed method to radiolabel carboxylic acids with [11C]CO2 
Developing methods that avoid the requirement for boronic esters would be 
attractive. Unlike boronic esters, organohalides are widely commercially 
available, therefore, developing methods that carboxylate halides are of interest. 
We propose a simple methodology[3] that uses nickel (II) and [11C]CO2 directly 
from the cyclotron to radiolabel organohalides (Scheme 5.2).  
 
Scheme 5.2. The proposed method for the synthesis of [11C]carboxylic acids using [11C]CO2 
Results from this project are not covered in this thesis however, preliminary 
results indicate that [11C]CO2 is not trapped within the reaction mixture. Future 
work will include screening the reaction mixture with various trapping reagents 
such as DBU, BEMP and tetramethylethylenediamine. Once a high trapping 
efficiency is achieved, experiments will then be performed in several polar 
solvents with the aim to identify the best solvent for the reaction. Reactions will 
also be performed at different temperatures, times and reagent concentrations as 
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